Aberrant Glycosylation In Pancreatic Cancer Progression by Chugh, Seema
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Theses & Dissertations Graduate Studies 
Spring 5-6-2017 
Aberrant Glycosylation In Pancreatic Cancer Progression 
Seema Chugh 
University of Nebraska Medical Center 
Follow this and additional works at: https://digitalcommons.unmc.edu/etd 
 Part of the Biochemistry Commons, and the Cancer Biology Commons 
Recommended Citation 
Chugh, Seema, "Aberrant Glycosylation In Pancreatic Cancer Progression" (2017). Theses & Dissertations. 
201. 
https://digitalcommons.unmc.edu/etd/201 
This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It 
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
i 
 
ABERRANT GLYCOSYLATION IN PANCREATIC 
CANCER PROGRESSION  
By  
SEEMA CHUGH 
 
 
A DISSERTATION 
 
Presented to the Faculty of  
The University of Nebraska Graduate College  
In Partial Fulfillment of Requirements 
For the Degree of Doctor of Philosophy 
 
 
Department of Biochemistry and Molecular Biology 
Graduate Program 
 
Under the Supervision of Professor Surinder K. Batra 
University of Nebraska Medical Center 
Omaha, Nebraska 
April, 2017
ii 
 
Aberrant glycosylation in pancreatic cancer progression 
Seema Chugh, Ph.D. 
University of Nebraska, 2017 
Advisor: Surinder K Batra, Ph.D.  
Aberrant changes in O-glycosylation patterns underlie pancreatic ductal 
adenocarcinoma (PDAC) progression and metastasis. Glycosylation is a post-
translational modification in which carbohydrate moieties are attached to the protein 
substrate. My dissertation is focused on mucin-type O-glycosylation, which is the 
predominant form of O-glycosylation and is regulated by a myriad of glycosyltransferases. 
PDAC is one of the most lethal diseases and the mechanistic involvement of 
aberrant O-glycosylation in its progression and metastasis is unknown. The aberrant 
glycosylation refers to the appearance of unusual carbohydrate structures such as 
truncated carbohydrate antigens, often referred to as tumor-associated carbohydrate 
antigens.  
In this dissertation, my goal was to investigate the role of aberrant glycosylation in 
pancreatic cancer progression. Aberrant glycosylation is attributed to dysfunction in 
expression/activity of glycosyltransferases. Prior published studies and our preliminary 
studies indicate loss of expression of O-glycosyltransferases-GALNT3 and C1GALT1 in 
PDAC. GALNT3 (N-acetylgalactosaminyltransferase 3) is a member of GALNT 
superfamily of enzymes that initiates mucin-type O-glycosylation. The second step of 
mucin-type O-glycosylation is catalyzed by C1GALT1 (Core-1 β-3 galactosyltransferase). 
My thesis is primarily focused on deciphering the mechanistic role of the first enzyme 
(GALNT3) and a second enzyme (C1GALT1) of mucin-type O-glycosylation in PDAC 
progression and metastasis.  
My results show that GALNT3 is differentially expressed during pancreatic cancer 
progression. Decreased/loss of expression of GALNT3 was seen in poorly differentiated 
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PDAC as compared to well-differentiated PDAC. This instigated further examination of the 
functional role of GALNT3 in pancreatic cancer. I performed GALNT3 knockdown studies 
in four different pancreatic cancer cell lines, and the knockdown cells had altered EGFR 
and Her2 glycosylation, increased growth, and metastasis.  
Apart from GALNT3, which catalyze the first step of O-glycosylation, I have also 
studied the role of a second enzyme, C1GALT1, in PDAC. C1GALT1 expression studies 
indicate loss of this glycosyltransferase in a subset of PDAC patients. Further, the 
expression was dramatically decreased in poorly differentiated PDAC as compared to 
well-differentiated PDAC. To study the functional implications of the loss of C1GALT1 in 
PDAC, I performed CRISPR/Cas9-mediated C1GALT1 knockout in two different PDAC 
cancer cell lines. Knockout of C1GALT1 in PDAC cells lead to aberrant MUC16 
glycosylation, increased tumorigenicity and metastasis. 
To further elaborate on the functional role of C1galt1, I have developed the 
KrasG12D; Trp53R172H/+; C1galt1loxP/loxP; Pdx1-Cre (KPCC) mouse model, by crossing 
C1galt1loxP/loxP mice with KrasG12D; Pdx1-Cre and Trp53R172H/+mice. Knockout of C1galt1 
along with Kras and p53 mutations (KPCC mice) significantly decreased overall survival 
as compared to KPC mice that have Kras and p53 mutations. Early tumors and metastasis 
were seen for KPCC mice as compared to KPC mice.  
In conclusion, I have experimentally shown that the loss of GALNT3 and C1GALT1 
in PDAC results in aberrant glycosylation that contributes towards PDAC progression and 
metastasis.
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CHAPTER 1A 
Introduction 
The material covered in this chapter is the subject of 1 published review article 
 
1. Chugh S, Gnanapragassam VS, Jain M, Rachagani S, Ponnusamy MP, Batra SK. 
Pathobiological Implications of Mucin Glycans in Cancer: Sweet Poison and Novel Targets 
Biochim Biophys Acta. 2015; 1856(2):211-25.
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1. Synopsis 
 
Mucins are large glycoproteins, which are expressed on epithelia as a protective barrier 
against various harsh insults mediated by toxins and pathogenic microbes. They are 
classified primarily as secreted and membrane-bound forms, and both mucin types are 
involved in various pathophysiological functions such as inflammation and cancer. High 
molecular weight of these proteins is attributed to their large polypeptide backbone 
extensively embraced by glycans. These glycan moieties on mucins modulate their 
function and hence play an important role in various physiological functions. Deregulation 
of glycosylation machinery results in altered mucin glycosylation during cellular 
transformation, and aberrant glycan structures play an active role to support malignancy. 
This review describes the functional implications and pathobiological significance of 
altered glycosylation of mucins in cancer. Further, the article delineates various factors 
such as glycosyltransferases and tumor microenvironment that contribute to dysregulation 
of mucin glycosylation during cancer. Finally, the scope of mucin glycan epitopes as 
potential diagnostic and therapeutic targets is discussed.
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1. Introduction 
Mucins are a family of high molecular weight glycosylated proteins with complex 
molecular organization. So far, twenty-one mucin genes have been identified and based 
on their structural organization, they are mainly classified as secreted and membrane-
associated forms [1, 2]. Both of these mucin classes are involved in epithelial cell 
homeostasis by acting as a protective shield against severe environmental insults [3]. 
MUC2, MUC5AC, MUC5B, MUC6, MUC7 and MUC19 are secretory mucins, which lack 
transmembrane domains and have a common von Willebrand factor D domain (vWF-D) 
and C terminus cysteine knot domain that are required for their oligomerization [4]. The 
transmembrane mucins constitute another important class of mucins, which includes 
mucins like MUC1, MUC3, MUC4, MUC12, MUC16 and MUC17. These are anchored on 
the cell surface via their transmembrane domains and are involved in various signaling 
pathways through their short cytoplasmic tails [5].  
Intricacy in the structure of these secretory and membrane proteins is imparted by 
their large polypeptide chain and various post translational modifications such as 
glycosylation, sulfation and phosphorylation [6-8]. Glycosylation is one of the major post 
translational modifications that defines these mucins and impacts their function. Mucins 
can be O-glycosylated or N-glycosylated. Both forms of glycosylation occur in distinct 
subcellular compartments, and differ by the amino acid involved and covalent attachment 
of the carbohydrates [9]. N-glycosylation of mucins is initiated in the endoplasmic reticulum 
(ER) by the action of UDP-GlcNAc phosphotransferases, whereas mucin type O-
glycosylation occurs in the golgi and is mediated by a family of enzymes known as UDP-
GalNAc: polypeptide GalNAc-transferases (GalNAc-Ts/GALNTs) [10, 11]. O-glycosylation 
is the major post-translational modification on mucins and occurs predominantly in the 
central tandem repeat domain that is common to all the mucins and is rich in proline, serine 
and threonine (PTS) residues [12]. The extent of O-glycosylation on mucins is determined 
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by the length and the number of PTS repeats, that are distinct to each mucin and variable 
in the same mucin due to gene polymorphism [12].  
Carbohydrate structures on mucin polypeptides dictate their biochemical and 
biophysical characteristics and determine their biological functions. For instance, mucin 
glycans act as a steric barrier, which excludes large molecules and blocks adhesion in a 
non-specific manner [6, 13]. Some of the glycan structures are also involved in mediating 
cellular interactions like that with leukocytes [14]. Here, we discuss the pathobiological 
significance of altered mucin glycosylation in cancer. Importantly, we have focused on 
how several oligosaccharide structures displayed by this class of biomolecules are 
involved in cancer progression. We have also discussed regulation of mucin glycosylation 
by several factors such as glycosyltransferases and tumor microenvironment. 
Nonetheless, with the recognition of these carbohydrate structures as tumor associated 
antigens (TAA), their potential involvement in diagnostics and therapeutics is discussed.  
 
2. Mucin glycosylation 
Glycosylation is the principal post translational modification that is the hallmark of 
these mucins. Mucins undergo both O and N-linked glycosylation, depending on the amino 
acid which is attached to the glycans. Both forms of glycosylation occur in distinct cellular 
regions and contribute to the biochemical, biophysical and functional properties of mucins 
[9]. 
2.1. N-linked glycosylation 
Protein N-glycosylation is initiated by the transfer of N-acetyl glucosamine 
phosphate (GlcNAc-P) to the polyisoprenol lipid precursor, dolichol phosphate (Dol-P), 
that results in the formation of dolichol pyrophosphate N-acetyl glucosamine (Dol-P-P-
GlcNAc) (Figure 1.1). This occurs on the cytoplasmic face of the ER and is mediated by 
the action of UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosamine-
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phosphotransferase (DAPGT1/GPT). Following this, another molecule of GlcNAc and five 
mannose (Man) residues are transferred sequentially by specific glycosyltransferases to 
generate Man5GlcNAc2-P-P-Dol. Subsequently, the dolichol-linked glycan precursor 
translocates to the ER lumen by the action of flippase. Further, transfer of four mannose 
and three glucose (Glc) glycans from Dol-P-Man and Dol-P-Glc, respectively, completes 
the synthesis of N glycan precursor Glc3Man9GlcNAc2-P-P-Dol, which is then transferred 
en bloc by oligosaccharyl transferase (OST) to the asparagine residue, in one of the 
prominent N glycosylation sites of the nascent protein (Asp-X-Ser/Thr). A series of 
enzymatic processing reactions inside the ER trim this fourteen sugar N-glycan structure, 
following which the nascent glycoprotein is transported to the Golgi by COPII-coated 
vesicles. [15, 16]. In cis Golgi, further processing involves the removal of mannose 
residues by means of mannosidases. The processed protein is then transferred to the 
medial Golgi, where hybrid and complex type N-glycans are added. N-glycan structures 
are further elongated by the addition of several repeats of LacNAc (-3Galβ1-4GlcNAcβ1-
) n. Finally, these elongated structures are capped by the addition of residues like sialic 
acid, N-acetylglucosamine and fucose [10].  
The number of N-glycosylation sites varies among mucin family members. For 
example, MUC1 has 5 potential N-glycosylation sites whereas MUC4 has more than 10 
putative N-glycosylation sites [17, 18]. N-glycosylation in mucins contributes to protein 
stability, folding and trafficking. In MUC2, N-glycosylation has been demonstrated to be 
critical for dimerization and ensures its correct folding inside ER [19]. Additionally, N-
glycosylation has been shown to play an important role in the surface localization of 
MUC17 [20]. 
2.2. O-linked glycosylation 
Although more complex and less understood than N-linked glycosylation, O-
glycosylation is the major post-translational modification that occurs on mucins (Figure 
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1.2). O-glycan chains attached to mucin polypeptide (apomucin) involves various 
monosaccharides such as N-acetylgalactosamine, galactose, N-acetylglucosamine, sialic 
acid and fucose. Arrangement of these sugars on mucins adds to structural diversity of 
oligosaccharide structures (as outlined in figure 1.2), that dictates their biophysical and 
functional characteristics. O-glycosylation of mucins is a multistep process and begins 
after the glycoproteins are exported to the Golgi by vesicle-mediated transport [9 and 21].  
Assembly of O-glycans is initiated with the addition of the first sugar, N-
acetylgalactosamine (GalNAc), to the serine/threonine amino acid in the PTS region by 
the activity of a superfamily of enzymes known GalNAc-Ts [22]. The first O-glycan formed 
by this family of enzymes is known as Tn antigen [23]. Based on the in vitro studies carried 
out earlier in 1990s, it has been established that efficient transfer of GalNAc occurs mainly 
to the threonine residue [24]. Till now, twenty GalNAcTs genes have been identified, which 
catalyze the initiation of mucin type O-glycosylation. Despite the functional redundancy 
among these GALNTs, varied substrate specificity and tissue specific expression of these 
enzymes have been reported [22]. The distinguishing feature of this class of 
glycosyltransferases is their lectin domain, which helps them in binding existing GalNAc 
residues on mucins. This increases their catalytic efficiency and allows them to complete 
the initiation of glycosylation before elongation of GalNAc residues begins. [25].  
GalNAc (Tn) is then processed by the activity of various glycosyltransferases that 
add distinct glycans. For instance, sialyl transferases add sialic acid to yield Sialyl-Tn 
(STn). Alternatively, the glycan chain can be elongated by various glycosyltransferases to 
give rise to various core structures. Till date, eight core structures have been recognized. 
Biosynthesis of core 1 structure begins by addition of galactose sugar to GalNAc by T-
synthase/Core 1 synthase (C1GALT1) that gives rise to a disaccharide structure known 
as Core 1/T antigen. The key molecule regulating activity of Core 1 synthase  is an ER 
chaperone molecule Cosmc (core 1 β3-Gal-T-specific molecular chaperone) [26]. 
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Mutations in Cosmc protein lead to the inactivation of Core 1 synthase, which is associated 
with Tn syndrome [27]. Core 1 is a critical glycan structure necessary for the formation of 
the core 2 glycan. Formation of core 2 glycan is catalyzed by core 2 beta-1, 6-N-
acetylglucosaminyltransferase (C2GnT), which adds N-acetylglucosamine to T antigen. 
Besides elongation to core 2 glycan, T antigen can also be modified by sialylation to sialyl 
T antigen.  
The first sugar, GalNAc can also be elongated to form core 3 and core 4 structures. 
The resulting core structure depends on the relative activity of glycosyltransferases.  
These O-glycans can also be extended by addition of several residues of poly-N-
acetyllactosamine. Further, these oligosaccharide chains can be terminally glycosylated 
by sialylation, fucosylation or sulfation. Terminal glycosylation often results in the 
formation of several carbohydrate epitopes such as Lex, Lea, SLex, SLea, which are 
commonly expressed by carcinoma mucins (Figure 1.2) . 
Mucin type O-glycans have been shown to contribute to viscoelastic properties of 
mucus and also protect apomucin backbone from attack by proteases. Additionally, a 
diverse array of glycans on mucins lining different intestinal regions also dictates their 
interactions with the gut microbiome [28]. This may also explain the specific colonization 
of microbiota in intestine. Peripheral oligosaccharide structures on mucins such as Lex, 
SLe x serve as ligands for bacterial fimbrial adhesins, thereby trapping them and 
preventing them to infect the underlying epithelia [29]. 
 
3. Role of mucin and its aberrant glycosylation in cancer 
3.1. Role of mucins in cancer pathogenesis 
Aberrant expression of mucins is observed in various malignancies, wherein they 
play an essential role in cancer pathogenesis [1, 30]. For example, MUC1 is involved in 
breast cancer pathogenesis as it affects several signaling pathways that influence disease 
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aggressiveness. The C terminal subunit of MUC1 acts as an oncoprotein, and through its 
interaction with various receptor tyrosine kinases such as EGFR and ErbB2, MUC1-CT 
activates PI3K-Akt and MEK-ERK pathways in breast cancer. Further, this 
transmembrane mucin is also found to be overexpressed in ovarian cancer and various 
gastrointestinal malignancies including pancreatic cancer [31, 32]. Similarly, MUC4-
another transmembrane mucin-is implicated in the pathobiology of various cancers, 
including pancreatic, breast, lung and cervical cancers. Several studies from our lab have 
very well established the involvement of MUC4 in various aspects of cancer progression 
like metastasis, evasion of apoptosis and induction of drug resistance [33-35]. MUC4 has 
been shown to promote breast and pancreatic cancer metastasis [33, 34]. Interestingly, in 
the case of ovarian cancer, MUC4 also plays a role in cancer stem cell maintenance via 
stabilization of HER2 [36]. MUC4 has also been shown to interact with and stabilize HER2 
in pancreatic cancer cells, but whether or not this interaction is involved in cancer stem 
cells needs to be explored [37].   
The largest transmembrane mucin identified till date is MUC16, which is also 
known as CA-125 and exhibits pro-tumorigenic and pro-metastatic properties [38]. MUC16 
is deregulated in ovarian cancer where it plays an important role in metastasis and protects 
the tumor cells from cytotoxic responses from natural killer cells (NK cells) [39] and [40]. 
Further, studies from our lab have also indicated the involvement of MUC16 in pancreatic 
cancer progression and in breast cancer proliferation [41, 42]. In pancreatic cancer cells, 
MUC16 has been reported to interact with GPI-linked protein, Mesothelin (MSLN), which 
leads to activation of MMP-7, an extracellular matrix remodeling enzyme, thereby resulting 
in enhanced pancreatic cancer cell motility and invasion [43]. In addition to MUC16, 
aberrant expression of MUC13 is also observed in many epithelial cancers but has not 
been significantly explored [44]. 
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Along with transmembrane mucins, expression of secreted mucins is also 
dysregulated in various malignancies. MUC5AC is one of most studied secretory mucins 
and has been demonstrated to be upregulated in various cancers including colorectal and 
pancreatic cancer [45]. Differential expression of MUC5B is also observed in several 
malignancies such as breast and colorectal cancer [32, 46]. MUC2 is equally important as 
it has been associated with colorectal cancer and is typically downregulated [47]. Overall, 
mucins play an important role in the pathobiology of various malignancies. 
3.2 Aberrant glycosylation of mucins in cancer  
Alterations in the composition and structure of mucin glycans have been observed 
in various malignancies [48-50]. During carcinogenesis, neo glycan structures emerge on 
various glycoproteins including mucins. These atypical glycan forms can result from 
incomplete glycosylation resulting in truncated structures, aberrant extension of glycan 
chains, or novel carbohydrate patterns [51, 52] (Figure 1.3). Mucins with reduced core 1 
and core 3 structures along with increased expression of Tn and STn are observed in 
intestinal, colon and pancreatic cancers [53, 54]. Tn, TF and SLex are carbohydrate 
epitopes commonly observed on MUC1 in cancer [55]. Evidence for the abnormal 
carbohydrate structures on mucins emerged from earlier studies demonstrating increased 
expression of TF antigen on mucin in colonic adenocarcinoma and ulcerative colitis as 
compared to normal colon [56]. Unusual glycan structures formed on these glycoproteins 
during cancer are involved in cancer biology. The role of these aberrant glycans in cancer 
cell adhesion, motility, invasion and altering the interaction of cancer cells with other cells 
such as lymphocytes and endothelial cells has been well documented [53]. Apart from the 
the pathologic role of these atypical mucin glycans, these aberrant glycan structures also 
constitute tumor associated carbohydrate antigens (TAA), which are extensively used as 
diagnostic markers.  
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4. Pathologic role of mucin glycans in cancer 
Accumulating evidence suggest that deregulated expression of mucin glycans significantly 
influences the function of the mucins in pathological conditions.  
4.1. Mucin glycans in mediating cellular interactions 
The glycophenotype of cell surface mucins dictates both homotypic and 
heterotypic cellular interactions. These glycan moieties on mucins serve as ligands for 
various carbohydrate binding proteins, such as galectins, selectins and Siglecs and 
mediate diverse biological processes, including cell adhesion, migration, trafficking and 
inflammation [53]. All of these glycan-binding receptors constitute the lectin family and are 
expressed by specific subsets of cells such as immune cells and endothelial cells.  
4.1.1. Galectins 
Cancerous conditions are often accompanied by altered expression of beta 
galactoside binding lectins known as galectins [57] and [58]. These are soluble lectins with 
immunomodulatory activity and have been shown to regulate the proliferation and 
apoptosis of T cells [59]. Various mucins offer binding sugars for galectins. Like it has 
been shown in our lab, MUC4 interacts with galectin-3 via T antigens on its surface [60]. 
Further, MUC1 and MUC16 has also been shown to interact with galectin-3 in various 
cancers [61-63].  
4.1.2. Selectins 
Selectins are adhesion molecules which recognize galactose-containing 
carbohydrates on their cognate ligands [64]. Depending on the cell types on which they 
are expressed, selectins are classified into E-selectin (endothelial cells), L-selectin 
(Leukocytes) and P-selectin (platelets). These selectins recognize sialylated/sulfated 
lewis antigens on mucin glycoproteins, which are highly expressed during cancerous 
conditions [65]. The interaction of selectins with secreted and surface mucins is well 
depicted in colon cancer cells where they have been shown to induce platelet aggregation 
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and agglutination of activated PBMCs [66]. This may also explain platelet containing 
microthrombi generally observed in mucinous cancers [67]. 
4.1.3. Siglecs (Sialic acid-binding immunoglobulin-type lectins) 
Sialic acid binding lectins or Siglecs are expressed by some hematopoietic cells 
such as macrophages and B cells, and play an important role in modulating the immune 
response. Siglecs have been demonstrated to interact with mucins. For instance, Siglec-
9 expressed on surface of immune cells such as B-cells, monocytes and NK cells has 
been shown to interact with MUC16 and MUC1 [68, 69]. 
4.2. Functional consequences of mucin glycotopes-mediated cellular interactions 
Interaction of mucin glycans with sugar-binding poteins have been shown to affect 
several aspects of tumor progression such as tumor growth, escape of immune 
surveillance and metastasis (Figure 1.4). 
4.2.1. Mucin glycans in tumor growth 
Sialoglyans expressed on mucins have been shown to affect tumor growth. 
Sialoglycans on MUC1 (SLex) mediates its binding to Siglec-9, which is commonly 
expressed by immune cells. This binding induces recruitment of β-catenin to MUC1-C 
domain and its translocation to nucleus resulting in increased proliferation of cancer cells 
[68] (Figure 1.4a). 
4.2.2 Role of mucin glycans in the evasion from immune surveillance 
Although tumor tissues are characterized by infiltration of immune cells, such as 
macrophages, natural killer cells and cytotoxic T cells, tumor cells effectively escape 
immune surveillance. This is due to the activation of various immunosuppressive 
pathways activated by the tumor cells [70]. A considerable body of evidence suggests the 
involvement of glycan epitopes on cancerous cells in escape of immune surveillance. 
Elongation of mucin glycans beyond the Tn antigen alters their susceptibility towards NK 
and CTL-mediated killing [71] (Figure 1.4b). This has been shown in breast (T47D) and 
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pancreatic cancer cells (Capan1), wherein knock out of Cosmc protein (chaperone for 
core1 synthase) resulted in inhibition of glycan elongation beyond Tn, which consequently 
increased their sensitivity towards immune attack via NK cell-mediated antibody 
dependent cell cytotoxicity (ADCC) and cytotoxic T lymphocytes (CTL). Further, reverse 
correlation was observed between MUC1/MUC16 expression and immune killing, which 
suggests that upregulated expression of these mucins along with their glycan elongation 
beyond Tn can possibly be involved in immune evasion [71] . 
4.2.3. Mucin glycotope-mediated cancer metastasis 
Interaction of mucin glycans with selectins has been implicated in metastasis. 
Several studies have demonstrated that cancer metastasis involves interaction between 
carcinoma mucins on cancer cells and P-selectin on platelets [72]. Further, in ovarian 
cancer, N-glycans on MUC16 are implicated in facilitating peritoneal metastasis via their 
interaction with mesothelin expressed by mesothelial cells lining the peritoneal cavity [73].  
Interaction between galectin-3 and MUC4 has been implicated in metastasis where 
galectin-3 binding results in MUC4 clustering, that exposes adhesion molecules such as 
integrins which in turn facilitates the attachment of tumor cells with endothelial cells 
(Figure 1.4c) [74]. Similarly, elevated circulating galectin 3 in several cancers has been 
shown to interact with TF on MUC1 and expose surface ligands for endothelial cells such 
as CD44. Hence this interaction abrogates the "shield effect" of MUC1 in preventing the 
adhesion of cancer cells to endothelial cells, thereby resulting in enhanced metastasis 
(Figure 1.4c) [63]. 
More recently, it has been shown that altered glycans on MUC1 impacts invasion 
and migration of breast cancer cells by influencing its interaction with CIN85, an adaptor 
protein involved in invasion and cytoskeletal alterations [75]. This was demonstrated by 
overexpressing some of glycosyltransferases such as ST6GalNAc1 and ST3Gal1, which 
are involved in the biosynthesis of carbohydrate antigens, STn and ST respectively. 
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Increased interaction of CIN85 and MUC1 was observed with increased expression of 
STn whereas this interaction was not altered with increased expression of ST [76]. This 
suggests that hypoglycosylated form of MUC1 (MUC1-STn) can promote MUC1’s 
interaction with CIN85 that results in increased migration and invasion. 
4.2.4. Role of glycosylation in membrane trafficking of mucins 
Most of the aforementioned processes mediated by mucin glycans such as 
metastasis and tumor growth necessitate the membranous localization of these 
glycoproteins. Both N- and O- linked oligosaccharides on some of these mucins are 
identified to contain tremendous information for their apical sorting. This has been well 
described for MUC1 using Madin Darby Canine Kidney cells (MDCK), with which it was 
demonstrated that O-glycosylated tandem repeats on MUC1 serve as apical sorting signal 
[77]. Several studies have suggested the involvement of these O and N glycomoieties in 
the membrane trafficking of their carrier protein. This was shown using benzyl-N-acetyl-α-
galactosaminide (BGN) and tunicamycin, commonly used drugs which interfere with O 
and N-glycan biosynthesis. Incubation of human colorectal adenocarcinoma cells (HT29) 
with BGN decreases secretion and membrane targeting of MUC1 [78]. Consistent with 
this study, treatment of endometrial and breast cancer cells with these inhibitors also 
reduced the expression of MUC1 on their surface [79]. These studies highlight the 
essential role played by mucin glycosylation in their membrane trafficking. However, the 
possible role(s) of glycans in apical sorting of other mucins such as MUC4 and MUC16 
need to be investigated.  
While glycosylation impacts trafficking, altered cellular trafficking can also impact 
mucin glycosylation. This concept was demonstrated for MUC1, wherein secretory and 
membrane-shed MUC1 probes displayed altered glycosylation profile. Secreted MUC1 
form (MUC1-S) exhibited more of core2 glycan structures whereas membrane-shed form 
was rich in sialylated core-1 glycan structures [80].  
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4.2.5 Mucin glycans and cancer stem cells 
Recently, mucins have been associated with cancer stem cells (CSCs).  Since 
alterations in mucin glycosylation have been implicated in cancer growth and metastasis, 
there is a possibility that CSCs have a greater tendency for altered glycosylation of mucins. 
A few studies have suggested altered glycosylation of mucins in these highly tumorigenic 
cells. Studies from our lab utilizing ovarian cancer cells ectopically overexpressing MUC4 
indicated a slight decrease in the molecular weight of MUC4 in the enriched side-
population as compared to non-side population [36]. Altered glycosylation may be a 
plausible mechanism for such observation but this remains to be investigated. Another 
study has reported the existence of hypoglycosylated MUC1 in the cancer stem cell 
population in MCF-7 breast cancer cells [81]. More comprehensive studies are required 
to decipher the role of mucin glycosylation in development and maintenance of cancer 
stem cells. 
 
5. Regulation of mucin glycosylation 
Given the functional significance of aberrant mucin glycans in cancer, it is 
important to understand how mucin glycosylation is regulated. Several factors influence 
the differential expression of mucin glycans during carcinogenesis. These include 
alterations in glycogene expression, altered localization of the glycosyltransferases, 
aberrant activity of respective glycosyltransferases/glycosidases, changes in golgi pH, 
efficiency of the sugar nucleotide transporters, and physiological alterations in the tumor 
microenvironment such as hypoxia and inflammation [82, 83].  
5.1. Mucin glycosyltransferases 
The glycogenes consist of either glycosyltransferases (GTs) that are responsible 
for synthesizing glycan structures, or glycosidases (Gs) that catalyze the release of 
glycans from glycoproteins and glycolipids. The relative level and activity of GTs and Gs 
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dictate the glycan profiles of glycoproteins and any imbalance results in aberrant 
glycosylation [84]. 
5.1.1 Altered glycogene expression during cancer 
Diversity in the expression of GTs and Gs in a cell is manifested in the variety of 
glycans displayed by mature mucins [85]. In general, cancer-associated glycan expression 
is regulated by myriad of glycogenes, some of which are transcriptionally repressed while 
others are induced during malignant transformation [86 and 87]. Genetic and epigenetic 
silencing mechanisms are involved in the inactivation of many glycogenes during 
carcinogenesis. For instance, in pancreatic and biliary tract carcinomas, elevated 
expression of CA19-9 (sialyl Lewis a-SLea) on core 1 or core 2 glycan structures has been 
detected as compared to the normal epithelia, which predominantly express disialyl Lewis 
A. CA19-9 is associated with mucins, which play significant roles in cancers and 
specifically pancreatic cancer [88]. This reduced expression of disialyl Lewis A during 
oncogenic transformation is due to the epigenetic silencing of the glycogene 
ST6GALNAC6 [89]. Similarly, normal colonic epithelial cells express 6 sulfo-sialyl–Lewis 
x, which is undetectable in colon cancer cells. Colon cancer cells, in contrast, expresse 
high levels of sialyl–Lewis x (SLex), which is due to epigenetic silencing of diastrophic 
dysplasia sulfate transporter (DTDST), resulting in insufficient sulfation and increased 
expression of SLex [90]. Additionally in colon cells, activity of core 3 synthase is 
suppressed by promoter methylation and its ectopic overexpression reduces cancer cell 
motility, suggesting that cancer cells downregulate this enzyme to enhance their 
metastatic potential [91]. Further, in gastrointestinal tissues, decreased expression of Sda 
that is expressed in the normal stomach is attributed to CpG island promoter 
hypermethylation of β4GALNT2. Absence of this glycogene favors the expression of the 
SLex and SLea which serve as ligands for selectins and are involved in metastasis. Stable 
expression of β4GALNT2 glycosyltransferase in colorectal (HT29) and gastric cancer cells 
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(KATOIII) leads to reduced expression of SLex and SLea and decreased metastasis [92]. 
More recently, it has been shown that the O-glycosylation-initiating enzyme GALNT3 is 
hypomethylated and is overexpressed in epithelial ovarian tumors [93]. Knockdown of this 
enzyme is associated with increased adhesion and decreased MUC1 stability, which 
suggest that the involvement of GALNT3 in ovarian cancer progression is possibly via 
aberrant MUC1 glycosylation [94]. Thus, the epigenetic regulation of the glycogenes 
significantly contributes to cancer progression and metastasis.  
In addition to epigenetic mechanisms, post-transcriptional regulation of GTs has 
also been reported recently. During the metastasis of melanoma, the expression of the O-
glycosylation-initiating GalNAc transferase, GALNT7, is down regulated by the increased 
expression of miR-30b/30d. Knockdown of miR-30b/30d restores GALNT7 expression 
that results in decreased cellular invasion and the induction of IL-10 (an 
immunosuppressive cytokine) [95].  
5.1.2. Localization of glycosyltransferases in normal and cancer cells 
Various glycosylating enzymes are distributed non-uniformly inside golgi, with 
each compartment expressing unique set of glycosyltransferases. Several factors dictate 
their golgi localization, some of which are intrinsic structural features of these enzymes. 
Predominantly, these glycosyltransferases are type II integral proteins which are 
organized in to N-terminal, cytoplasmic tail, transmembrane and the stem regions (CTS). 
These regions are involved in directing their golgi localization [96]. Transmembrane 
domain (TMD) of α-2, 6-sialyl transferase (ST) affects its golgi distribution. Mutagenesis 
studies have revealed that the length of TMD serves as a sorting signal, and varying the 
length of TMD alters the golgi retention of this trans Golgi enzyme [97]. Compartmental 
identity of medial Golgi enzymes like mannosidase II and MGAT1 (α-1,3-mannosyl-
glycoprotein 2-beta-N-acetylglucosaminyltransferase)  is maintained through their 
oligomerization mediated by their luminal regions [98]. Differential ratio of 
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glycerophospholipids (GPL) and sphingolipids (SL) among individual Golgi compartments 
(SL/GPL being highest in trans golgi and lowest in cis) also account for non-homogenous 
distribution of these enzymes [96, 99, 100]. For other glycosyltransferases like β-1,-
galactosyltransferase (GalT2), β-1, 4-N-acetylgalactosminyltransferase (GalNAcT) and 
sialyltransferase (SialT2), calcium-binding proteins like calsenilin and calsenilin like 
protein (CALP) have been shown to influence Golgi localization. GalT2 directly interacts 
with calsenilin via its cytoplasmic tail and this interaction impacts their mutual subcellular 
localization, whereas the localization of SialT2 and GalNAcT is mediated through their 
interaction with GalT2 [101]. Relative position of these glycosyltransferases inside the 
golgi determines the glycan structure produced by the cells. Aberrant glycosylation in 
various pathological states can be attributed to anomalous localization of 
glycosyltransferases.  
5.2. Effect of tumor microenvironment on mucin glycosylation 
In addition to the aforementioned cell-intrinsic determinants, various factors in the 
tumor microenvironment such as hypoxia and inflammation can modulate glycans on 
carcinoma mucins. 
5.2.1. Hypoxia-induced glycogene expression 
Hypoxic microenvironment prevails in the advancing tumor niche. Hypoxia induces 
neo-angiogenesis, directs the intracellular metabolism to anaerobic glycolysis and 
increases the metastatic potential of the cancer cells. Such hypoxic conditions also result 
in altered glycans structures due to transcriptional deregulation of various glycogenes like 
sialyl transferase, fucosyltransferase and sugar transporters. Certainly, hypoxia condition 
induces hypoxia induced factor (HIF) that results in increased expression of SLea and SLex 
in colon cancer cells. These selectin ligands were increased due to the increased 
expression of UDP-galactose transporter-1 expression (UGT1), sialyltransferase 
(ST3Gal-I), and fucosyltransferases (FUT-7) [102]. Abnormal glycan structures with 
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increase of N-glycosyl sialic acid residues are also prevalent in hypoxic conditions. This 
is attributed to Sialin, a sialic acid transporter, which is activated under hypoxia and 
promotes the incorporation of the N-glycolyl neuraminic acid (Neu5Gc) in mucin type 
glycans [103]. Notably, distinct sets of glycans are induced by hypoxia under malignant 
versus nonmalignant conditions, such as ischemic disorders, suggesting their distinct 
roles in distinct pathological conditions [86]. 
5.2.2. Inflammation and altered glycosylation 
Inflammation associated with several pathological conditions such as Helicobacter 
pylori infection, inflammatory bowel disease (IBD) and cancer also contributes to changes 
in glycosylation of many proteins [104-106]. For instance, inflammation is associated with 
changes on surface glycans of lymphocytes with an increase in sulfated carbohydrate 
epitopes that mediate transient interactions with selectins on endothelial cells, which 
facilitates the homing of activated lymphocytes to inflammed sites [107, 108]. Similarly, 
inflammatory conditions have also been shown to modulate the glycan profile of various 
mucins on cancer cells [109]. 
This has been described in research carried out by Brian B. Haab group in Van 
Ander Research Institute, wherein by stimulating pancreatic cancer cells (Aspc-1, BxPC-
3 and SU.86.86) with various inflammatory cytokines such as IFNγ, IL-1α and TNFα, 
significant changes in mucin glycosylation and their expression were observed. Using 
immunoprecipitation and antibody microarrays, they demonstrated that TNFα and IFNγ 
stimulated BxPC-3 cells display elevated CA 19-9 levels on MUC1 and MUC5AC. 
Elevated levels of terminal GlcNAcβ, GalNAcα, GalNAcβ and lactosamine were observed 
on MUC16 in MIA PaCa cells [83]. These experiments highlight the impact of inflammation 
on mucin glycans in cancer. Additional studies are required to determine the underlying 
mechanisms involving inflammation-mediated glycan changes on mucins.  
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Interestingly, some of the studies have described the crosstalk between 
inflammation and glycosylation, wherein they have shown that many glycosylation 
changes can also contribute to inflammation [110]. Further research to investigate whether 
such autocrine loop exists between mucin glycosylation and inflammation in cancer will 
be intriguing. 
5.3. Impaired mucin glycosylation with elevated pH  
The ability of Golgi to facilitate essential functions such as protein folding, 
glycosylation, sorting and trafficking relies on its luminal pH. Any aberrations in organelle 
pH interferes with all these events which results in abnormalities associated with several 
pathological consequences such as cystic fibrosis and cancer [111, 112]. While altered 
glycosylation profile of mucins in several cancers is attributed mislocalization of GTs, there 
is also evidence supporting the involvement of altered golgi pH in aberrant glycosylation. 
In breast and colorectal cancer  cells, increased Golgi pH is associated with expression of 
T antigen, a core 1 carbohydrate structure usually associated with carcinoma mucins 
[113]. However the exact mechanism by which these changes occur remains unclear.  
 
6. Diagnostic and prognostic significance of mucin glycans 
Early diagnosis is the key for improving the clinical outcome of all malignancies 
and mandates the development of efficient diagnostic tools. Serum biomarkers are 
clinically acceptable and more preferred over other diagnostic modalities such as CT scan, 
MRI and endoscopy due to their non-invasive nature and relatively cost effectiveness. In 
fact, aberrant mucin glycans have been the basis of several clinically approved 
serodiagnostic tests for various malignancies [114]. CA-125, used in the diagnosis of 
ovarian cancer, is an epitope present on MUC16  while CA15-3, an epitope on MUC1, is 
used to monitor breast cancer [115, 116]. Altered expression of mucin glycans is a 
hallmark of several malignancies including pancreatic, breast, gastric, colon and lung 
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cancer [117]. Since these unusual glycan structures are generally not seen in normal 
tissues, these mucin glycotopes can potentially serve as efficient diagnostic tools. Several 
glycan epitopes have been approved by the FDA as biomarkers for diagnosis or utilized 
to monitor response to therapy or disease progression. A well-documented example of 
such a marker is CA19-9 , which is of clinical utility in various gastrointestinal cancers and 
is often used for diagnosis of pancreatic cancer [118] .This serological assay detects 
aberrant changes in SLea  which is highly expressed on mucins. Similarly, CA72-4 assay 
is used to detect elevated levels of STn, an another carbohydrate antigen associated with 
mucins in several epithelial cancers [119]. 
Due to extremely low abundance during early disease, rapid hepatic clearance and 
requirement of complexities associated with their characterization, discovery of glycan 
biomarkers is challenging [120]. As an alternative, a few studies have provided strong 
hope for the identification of glycan biomarkers by detecting anti-glycotope auto 
antibodies. During the onset of tumor, the immune system recognizes altered glycan 
epitopes as neoantigens and elicits humoral response resulting in the generation of auto-
antibodies. These auto-antibodies are highly specific and display exclusive affinity toward 
the host antigen as the disease progresses. These two unique features make the auto-
antibodies an effective diagnostic tool for the early detection of cancer, as well as 
monitoring the disease status. The presence of these autoantibodies towards 
glycopeptide regions (Tn-MUC1, STn-MUC1) of aberrantly glycosylated MUC1 has been 
demonstrated in breast, ovarian and prostate cancer [121]. 
Recently, existence of such auto-antibodies directed toward Tn and STn epitopes, 
and T antigen on MUC1, MUC4 and other mucins has been demonstrated by seromic 
profiling of colon cancer patients [122]. Among these auto-antibodies, the IgG type in 
serum of cancer patients specifically reacted with MUC1 glycopeptides while there was 
no reactivity with sera from healthy and IBD (Inflammatory Bowel Disease) controls. IgM 
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type showed reactivity to all the mucins with core 3 glycans. Thus, IgG type autoantibodies 
are highly specific to MUC1 and can be used to discern between cancerous and IBD 
patients. Further, their sera samples contained a higher amount of anti-MUC4 IgA type 
auto-antibodies. The study is also extended to other mucins (MUC2, 6, 7 and 5AC) 
however, MUC1 and MUC4 carry the most prominent tumor-associated glycan epitopes 
[122]. 
More recently, another group made an attempt to detect the combination of mucins 
and their associated glycans using proximity ligation assay (PLA). Using a set of samples 
from different types of adenocarcinomas such as colon, lung, breast and ovary, they 
suggested that this in situ technique can detect aberrant mucin glycoforms with better 
sensitivity and specificity than assays detecting only the O-glycans/mucins [123]. 
However, further studies with increased cohort size are required to annotate these 
aberrant glycoforms as cancer biomarkers. 
 
7. Glycans as therapeutic targets 
The presence of glycans on various biomolecules underscores their functional 
importance. Some of these molecules such as mucins are localized on the cell surface 
and can modulate the cellular functions during physiological and pathological conditions 
[6]. More specifically, mucin glycans are involved in tumor cell proliferation, invasion, 
hematogenous metastasis and angiogenesis. Thus, glycans are very attractive targets for 
cancer therapy. 
7.1 .Mucin glycan/glycopeptide vaccines   
A major limitation in targeting mucins peptides is posed by the normal homeostatic 
role played by their secreted and membrane-bound forms. Mucin glycopeptides-based 
vaccines may offer an added advantage in that the undesired effects on normal epithelial 
tissues are limited, as there is distinct glycan pattern on mucins of tumor cells as compared 
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to normal cells. Unusual glycomotifs on mucins are recognized by the immune system but 
they are poorly immunogenic; therefore administration of synthetic glycans along with 
carrier protein can be used as anti-cancer vaccines to boost immune response [124]. One 
such example is the STn-KLH vaccine, which was used in phase III clinical trials of breast 
cancer patients with metastatic disease and has been shown to induce both humoral and 
cellular immune responses [125, 126]. Another example of glycan vaccine is multicopy 
multivalent vaccines, where polymerized Tn carbohydrate antigen is conjugated with gold 
nanoparticles. In vivo experiments on New Zealand white rabbits using this vaccine have 
demonstrated significant immune responses along with crossreactivity towards Tn antigen 
on various mucins [127].  
A MUC1-based glycopeptide vaccine was designed by linking the glycopeptide 
antigen sialyl-Tn-MUC1 to tetanus toxoid. This vaccine induced a very strong and 
selective immune response in mice [128].  Since MUC1 glycopeptide is poorly 
immunogenic, synthetic vaccines consisting of MUC1 glycopeptide along with TH  (T 
helper) peptide have also been designed to activate humoral immunity [129]. Similarly, to 
stimulate the immune response, oligovalent vaccines have been constructed by 
conjugating MUC1 glycopeptide with toll-like receptor 2 (TLR2) lipopeptide ligands using 
Click chemistry [130]. More recently, MUC1 tripartite vaccines has been generated using 
MUC1 glycopeptide, TH  peptide and TLR2/9 agonist and were found to elicit a better 
immune response [131]. 
Currently, we are examining the MUC4-associated glycan epitopes and glycan 
interacting proteins in various cancers. This will lead to the development of novel 
diagnostic and therapeutic targets. Generating vaccines carrying both N- and O- 
glycosylated mucin peptides could be an effective therapy against various cancers. It is 
also important to investigate the possibility of other mucins such as MUC16 as a vaccine 
candidate, as it is highly overexpressed in pancreatic, breast and ovarian cancers [38]. As 
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multiple mucins are involved in malignant conditions, multivalent vaccines targeting many 
mucins could also be of great therapeutic potential. 
7.2 Glycosyltransferase inhibitors and glycomimetics as therapeutic agents 
Significant studies using individual glycans as therapeutic targets have been 
performed. The core glycan structures build the O-GalNAc glycans and their role has been 
studied intensively by several investigators. Besides this, the terminal glycans on mucins 
are also of unique importance due to their primary interactions with other proteins [69]. 
Sialic acid is the common terminal glycan on mucins. Interestingly a sialic acid molecule 
alone as a member of an epitope modulates several functions under given conditions and 
plays a major role in cancer metastasis by aiding the cancer cells in detaching from the 
primary tumor [132]. Thus the detached cancer cells metastasize by the aid of glycan 
epitopes, which are expressed on the mucins and other glycoproteins. Also the selectin 
ligands (e.g. sialylated Lewis antigen) carry α2, 3-linked sialic acid in their terminal regions, 
further highlighting the importance of this modification on glycans in cancer. The 
application of sialyltransferases inhibitors, such as soyasaponin, in combination with a 
cancer drug could be an effective dual-targeted therapy [133]. Several sialyltransferase 
inhibitors have also been tested; however, very few are potent in inhibiting the enzyme 
activity.  
Glycomimetic drugs have been examined to block selectin interaction with the 
endogenous glycans [134]. Acetylated derivatives of GlcNAcβ3GalβO-Nap and 
Galβ4GlcNAcβ1O-Nap have been tested as decoys to disrupt the biosynthesis of natural 
ligands for selectins. Similarly, the utility of acetylated F-4 GlcNAc as an inhibitor of lectin-
mediated ovarian tumor cell adhesion has been evaluated [135]. Recent studies indicate 
that fluorinated GalNAc metabolically alters glycan structures on mucins. The glycans of 
leukocyte PSGL-1 are altered, which reduces cell binding to selectins and inhibits the 
biosynthesis of chondroitin sulfate. Acetylated F-4GalNAc exhibits superior metabolic 
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inhibitory activity compared to the GalNAcα -OBenzyl inhibitor. Significant efforts have 
also been invested for synthesizing/isolating natural products to function as competitive 
inhibitors against their native substrates. Several of these small molecules that mimic the 
glycan epitope are currently undergoing clinical trials [136]. Much research should be 
carried out to identify effective glycan targets on mucins that aid in the progression of 
disease. Their discoveries will provide us the platform for designing systematic studies 
toward synthesis of therapeutic reagents.  
 
8. Conclusion and perspectives 
The glycosylation of mucins not only regulates their stability but also modulates 
their function. As discussed in this review, mucin glycosylation is altered during neoplastic 
transformation and cancer progression. This has formed the basis for the use of glycans 
as prognostic/diagnostic biomarkers. Glycosylation of mucins is influenced by several 
factors, such as epigenetic regulation and sub-cellular localization of glycosyltransferases 
and tumor microenvironment. Altered expression of specific glycosyltransferases 
promotes cancer cell metastasis by various mechanisms. This provides a greater 
opportunity to screen for the specific inhibitors for these enzymes. The knowledge of 
specificities of these enzymes and their tissue distribution is important for drug discovery, 
especially for those enzymes involved in alteration of glycan signature during cancer 
progression.  
Much improvement is required in generating mucin glycopeptide-based vaccines 
that offers more sensitivity and specificity than the current mucin-based vaccines. 
Interdisciplinary approaches are urgently required from basic to translational research to 
enable advancement toward this goal. 
Considerable interest in understanding the role of glycans in the versatile functions 
of the mucins is increasing. Further research is required to identify the functional 
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glycotopes on mucins that are responsible for cancer progression. To get a deep insight 
into the involvement of mucin glycans in cancer, animal models with modulated expression 
of glycosyltransferases such as GALNTs, core1 synthase and sialyltransferase should be 
developed. This will certainly help in elucidation of the functional significance of mucin 
glycosylation, not only in cancer but also in other acute and chronic diseases and will lead 
to the identification of useful prognostic, diagnostic and therapeutic targets.
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Figure legends 
Figure 1.1 N-glycosylation of mucins: N-glycosylation is initiated in the ER by the 
transfer of GlcNAc from UDP-GlcNAc to lipid molecule known as Dol-P. Further one 
molecule of UDP-GlcNAc and four molecules of mannose are transferred sequentially on 
GlcNAc-P-P-Dolichol, resulting in the formation of Man5GlcNAc2-P-P-Dol. This is followed 
by the translocation of this oligosaccharide-linked Dolichol to the lumen of ER. Successive 
addition of four molecules of mannose and three molecules of glucose forms 
Glc3Man9GlcNAc2P-P-Dol, which is transferred en bloc by OGT to Asn residue of mucin 
molecule.  N-glycans linked onto mucin molecule are further trimmed inside the ER and 
processed in golgi apparatus (complex N-glycan synthesis, elongation and capping) giving 
rise to mature N-glycans linked to mucin molecule.
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Figure 1.1 
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Figure 1.2 Overview of mucin type O-glycosylation: O-glycosylation is initiated by the 
activity of ppGalNAcTs, which will attach N-acetylgalactosamine to S/T (highlighted in 
yellow) residues in the tandem repeat region, resulting in formation of Tn antigen. Tn 
antigen formed can be extended by activity of core 1 synthase to generate T antigen/core 
1 antigen. Alternatively, Tn can be modified by sialyltransferase to sialyl Tn (STn). Core 1 
antigen can be further elongated to form core 2 structure. Further, core 2 structure is 
extended to several structures such as Lex, SLex, Lea, SLea . Tn can also be extended by 
activity of other glycosyltransferases to form several other core structures (core 3-8)
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Figure 1.3 Aberrant glycosylation of mucins during cancerous conditions: 
Differential glycosylation of mucins occurs in malignant conditions, resulting in truncated 
glycan structures such as Tn, STn, T, and several core 2 extended structures such as 
SLex and SLea. This aberrant glycosylation results from several factors such as altered 
glycogene expression, mislocalization of glycosyltransferases, abnormal golgi pH and 
tumor microenvironment.
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Figure 1.3 
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Figure 1.4 A schematic representation of mucin glycans-mediated cellular 
interactions: a.) Aberrant glycans structures such as SLex on MUC1 mediates tumor 
growth by binding to Siglec-9 on immune cells. This binding induces the translocation of 
beta-catenin to the nuclei of cancer cells, resulting in cell growth. b.) Extensive 
glycosylation of MUC16 helps tumor cells in escaping immune attack via NK cells. c.) 
Interaction between galectin-3 and T antigen on MUC1 prevents anoikis via homotypic 
aggregation of cancer cells as well as mediates docking of tumor cells to endothelial cells 
thereby resulting in metastasis
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1. Background and rationale 
Several mechanisms that contribute to increased cancer aggressiveness have 
been identified in recent years. These include genetic and epigenetic modifications, varied 
translation, altered metabolism and post-translational modifications [1-3]. Among several 
post-translational modifications underlying cancer progression and metastasis, 
glycosylation has been recognized to play an important role [4]. Glycosylation involves the 
addition of carbohydrate residues to the protein substrate. O- and N-glycosylation are the 
two types of glycosylation, which is based on the amino acid to which carbohydrate 
residues will be linked. In the case of O-glycosylation, carbohydrates are linked to the 
hydroxyl group of serine/threonine. N-glycosylation involves attachment of carbohydrates 
to the amide nitrogen of asparagine[5]. This dissertation is focused on O-glycosylation, 
specifically mucin-type O-glycosylation.  
Mucin-type O-glycosylation occurs in the Golgi and involves the addition of N-
acetylgalactosamine (GalNAc) to serine/threonine residues in the protein backbone by the 
family of enzymes known as UDP-GalNAc: Polypeptide N-
acetylgalactosaminyltransferases (GALNTs) [6]. The resultant carbohydrate structure is 
known as Tn carbohydrate antigen, which can be extended by the addition of galactose 
to form T carbohydrate (core-1) antigen. This reaction is catalyzed by the activity of 
Glycoprotein-N-acetylgalactosamine 3-beta-Galactosyltransferase (C1GALT1) [7]. This 
thesis is primarily focused on deciphering the mechanistic role of the first enzyme 
(GALNT3) and the second enzyme (C1GALT1) of mucin-type O-glycosylation in PDAC 
progression. 
The first step in the mucin-type O-glycosylation is catalyzed by GALNT family, 
which comprises 20 enzymes and have distinct substrate specificities despite their 
functional homology [8]. Differential expression of several GALNT genes has been 
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observed in several malignancies [9-11]. Prior studies in pancreatic cancer have reported 
a loss of one of the GALNT members, GALNT3, in poorly differentiated pancreatic cancer 
[12]. However, there is limiting information on how the loss of GALNT3 impacts PDAC 
aggressiveness. 
Further, studies have also reported dysregulated activity of the second enzyme 
(C1GALT1) of the biosynthetic pathway in malignant conditions [4]. Upregulated 
expression of C1GALT1 has been reported in hepatocellular carcinoma and breast cancer 
and is associated with increased tumor growth [13, 14]. On the contrary, loss of C1galt1 
activity in the colon has been shown to induce colitis, which is a major risk factor for colon 
cancer [15]. In the case of pancreatic cancer, studies conducted by two independent 
groups have demonstrated that loss of the molecular chaperone, Cosmc (core 1 β3-Gal-
T-specific molecular chaperone), which aids in proper folding and function of C1GALT1, 
potentiates oncogenesis [16, 17]. However, the precise involvement of C1GALT1 in PDAC 
has not been studied. 
2. Hypothesis 
 Based on the previous studies suggesting loss of expression of O-
glycosyltransferases, GALNT3, and C1GALT1 in PDAC, we hypothesized that loss of 
GALNT3 and C1GALT1 is associated with aberrant O-glycosylation and enhanced 
disease aggressiveness. 
3. Objectives 
Aim 1: To investigate the mechanistic role of GALNT3 in PDAC. 
Aim 2: To determine the functional implications of knockout of C1GALT1 in PDAC.  
Aim 3: To understand the role of C1GALT1 in PDAC progression and metastasis by use 
of KPCC (KrasG12D; Trp53R172H/+;  C1galt1loxP/loxP;  Pdx1-Cre) model.
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1. Tissue Samples from PDAC Patients 
After approval of the Institutional Review Board, formalin-fixed paraffin-embedded 
tissue specimens from pancreatic cancer patients who underwent Whipple surgery (n=30) 
were retrieved. Additionally, we also obtained tissue arrays (US Biomax -PA 1002a A009 
and BIC14011) that were representative of normal pancreatic tissues, chronic pancreatitis, 
PanIN lesions and PDAC (i.e., well-differentiated, moderately differentiated, and poorly 
differentiated cancer).  
 
2. Cell lines and cell culture 
Human microvascular endothelial cells (HMEC-1) were a kind gift from Dr. Rakesh 
Singh (University of Nebraska Medical Center) and were maintained in 5% RPMI 
supplemented with L-glutamine. Human pancreatic ductal adenocarcinoma (PDAC) cell 
lines CD18/HPAF, BxPC3, Capan-1, SW-1990 and T3M4 were obtained from the 
American Type Culture Collection (ATCC) and grown in recommended media 
supplemented with antibiotics (10% DMEM for CD18/HPAF, Capan-1, and T3M4 cells, 
and 10% RPMI for BxPC3 cells). These PDAC cells were maintained in a humidified, 
5% CO2 atmosphere at 37 °C. hTERT-Human Pancreatic Nestin Expressing cells (HPNE) 
and oncogenic transformed hTERT -HPNE-E6/E7/St/KRAS cells were a kind gift from Dr. 
Michel M. Ouellette [1]. All of these cell lines were tested mycoplasma-free before 
conducting the experiments.  
 
3. Stable GALNT3-knockdown PDAC cells 
Stable transfection of GALNT3 was performed by inserting a specific shRNA 
sequence (5’-GGTCTGATCACTGCTCGGT-3’) in the following four PDAC cell types: 
CD18/HPAF, BxPC3, Capan-1, and T3M4 cells. The Phoenix Packaging cell line was 
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transfected with scramble control and pSUPER-Retro-sh-GALNT3 using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA, USA). Viral particles collected at 48-hours post-
transfection were used to infect CD18/HPAF, BxPC3, Capan-1, and T3M4 cells. Stably 
transfected, pooled populations of GALNT3-knockdown cells were obtained using the 
antibiotic selection (puromycin, 4 μg/ml). GALNT3 knockdown-cells were maintained in 1 
μg/ml puromycin-selection media. 
 
3. CRISPR/Cas9 mediated knockout of C1GALT1 in PDAC cells  
Genomic depletion of C1GALT1 was carried out using CRISPR Vector (pX330-U6-
Chimeric_BB-CBh-hSpCas9 vector, Addgene) with C1GALT1 specific guide RNA 
sequence (GCAGATTCTAGCCAACATAA). At 2-3 weeks after transfection, VVA-
fluorescein-based FACS sorting was used to obtain C1GALT1 knockout clones. Complete 
knockout was confirmed by western blotting. Further, the region around guide RNA was 
PCR amplified and subjected to Sanger sequencing using primers described in Table 2.1. 
 
4. Genetically engineered mouse models. C1galt1loxP/loxP was a kind gift from Dr. Lijun 
Xia at University of Oklahoma Health Sciences Center. KPC (KrasG12D; Trp53R172H/+: Pdx-
Cre) and KPCC (KrasG12D; Trp53R172H/+; C1galt1loxP/loxP; Pdx1-Cre) were created by 
breeding of KrasG12D; Pdx1-Cre and LSLTrp53R172H/+ with C1galt1loxP/ loxP. Further, 
intercrossing of their F1 progeny resulted in the generation of KPCC mice along with KPC 
control littermates. All of the animals were backcrossed 12 times to C57BL/6 before 
carrying out the breeding. For progression studies, KPC, KPCC, and age-matched 
controls were euthanized at 3, 5, 10, 15 and 20 weeks of age (five animals/group/time 
point). Survival studies were also conducted on KPC and KPCC mice (8-10 
animals/group). All of the animal studies were performed in accordance with the U.S. 
Public Health Service "Guidelines for the Care and Use of Laboratory Animals" under an 
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approved protocol by the University of Nebraska Medical Center Institutional Animal Care 
and Use Committee (IACUC). 
 
5. DNA isolation and genotyping 
Mice at 15-21 days of age were tail clipped and DNA isolation was performed using 
standard protocols (Maxwell 16 mouse tail DNA purification kit, Promega, Madison, WI, 
USA). The genotyping of Kras, p53, Pdx-Cre, C1galt1loxP/loxP was performed by PCR using 
the primer sequences mentioned in Table 2.2.  
 
6. Orthotopic tumor mouse models 
For orthotopic tumor studies, 0.5x06 PDAC cells were injected into the pancreas of 6-8- 
week old nude mice (6 to 8 animals/group) using conventional procedures. Euthanization 
of experimental mice cohorts was performed 21-30 days after orthotopic transplantation. 
Following euthanization, tumor weights and metastatic lesions were recorded.  
 
7. Reagents and Antibodies 
Tables 2.1, 2.2, and 2.3 outline a thorough list of primers and antibodies used in 
the study. Biotinylated VVA (binds Tn carbohydrate antigen) and PNA (binds T 
carbohydrate antigen) lectins were purchased from Vector Labs.  
 
8. Immunohistochemistry (IHC) 
IHC staining was performed on Whipple samples to analyze GALNT3 and 
C1GALT1 expression using a previously described method [2]. Further GALNT3 staining 
was also performed on tissue arrays. Apart from patient tissues, IHC staining was also 
performed on KPC and KPCC mouse tissues Briefly, after deparaffinization and 
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dehydration of tissue sections, endogenous peroxidase activity in these human tissues 
was blocked by 3% H2O2 for an hour. Further, antigen retrieval is done by incubating these 
tissues with 0.01 M citrate buffer (pH 6.8). Subsequently, the tissue slides were blocked 
with horse serum, which was followed by their incubation with anti GALNT3 antibody for 
16 hr in a humidified chamber at 4°C. The specificity of the antibody was confirmed by 
using isotype control. The sections were probed with streptavidin-HRP and counterstained 
with hematoxylin. Expression of GALNT3 and C1GALT1 was analyzed by a pathologist. 
An intensity (0 - no staining, 1 – weak staining, 2 – moderate staining, and 3 – strong 
staining) and percentage of positive cells (range 1–4; 0–25% positive cells, equal score of 
1, 26–50%, equal score 2, 51–75%, equal score 3, and 76–100%, equal score 4) were 
recorded. A composite score, obtained by multiplying the two values, was assigned and it 
ranged from 0 to12.  
 
9. Immunofluorescence 
Confocal analysis of GALNT3 expression was carried out with CD18/HPAF, T3M4, 
and Panc-1 PDAC cells. All of these PDAC cells were grown in a 12-well plate dish to 60% 
confluence on autoclaved coverslips for 48 hours. After their fixation with 4% 
paraformaldehyde (10 minutes), these PDAC cells were permeabilized with 0.2% Triton-
X (15 minutes). Blocking was completed using 10% Bovine Serum Albumin (BSA) 
(Jackson Immunoresearch Labs, Inc., West Grove, PA, USA), which was followed by 
overnight incubation with a GALNT3 antibody at 4°C. The cells were then washed with 
phosphate-buffered saline (PBS) for 3 × 5 minutes and incubated in dark for 30 min with 
FITC-conjugated anti-mouse secondary antibody (Jackson Immunoresearch Labs, Inc.) 
at room temperature. Cells were washed again (5 × 5 minutes) in PBS and mounted on 
glass slides in Vectashield mounting medium that contained the nuclear staining dye DAPI 
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(Vector Laboratories, Burlingame, CA, USA). Additionally, we also performed 
immunofluorescence staining on mouse tissues using antibodies described in Table 2.3. 
 
10. Histology 
Formalin-fixed mouse tumor tissues were paraffin embedded and sectioned. Following 
sectioning, the tissues were subjected to H and E staining. KPC and KPCC tumor tissues 
were also stained with Picro-Sirius red and Alcian blue as per the recommended protocols.  
 
11. Real Time –PCR 
RNA is collected from PDAC cells using the RNAeasy kit (Qiagen, Valenica, CA, 
U.S.A.). Specifically, 1 μg of the RNA was converted to cDNA, which was further used for 
RT-PCR quantification of glycosyltransferases and EMT-related genes.  
 
12. Tumor endothelium cell adhesion assay 
Adhesion of cancer cells to activated endothelial cells was examined using 
CytoSelect™ Tumor-Endothelium adhesion assay kit (Cell Biolabs, San Diego, CA, USA) 
[3]. In brief, 10,000-20,000 HMEC-1 endothelial cells were cultured on collagen/gelatin 
coated 96-well plates (Black/Clear Flat Bottom-Corning™) till the formation of a 
monolayer. GALNT3-scrambled and -knockdown cells (CD18/HPAF and BxPC3) 
suspension pre-labeled with CytoTracker™ was placed in 96-well plates containing 
endothelial cells, and incubated at 37˚C for 1 hr. 96-well plates were then washed 3 times 
to remove non-adherent cells. Cell adhesion of labeled scrambled control and GALNT3- 
knockdown cells was determined by measuring the fluorescence using the fluorescent 
plate reader at an excitation wavelength of 480 nm and an emission of 520 nm. 
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Percentage adhesion is calculated as follows: % cell adhesion = mean fluorescence 
intensity of experimental wells/mean fluorescence intensity of total cells plated x100% 
 
13. Lectin Pull-down Assay and Immunoprecipitation 
Protein lysates (600 μg) collected from scramble control and GALNT3-knockdown 
cells were incubated with biotinylated VVA (5 μg) and PNA (5 μg) lectins to detect Tn and 
T carbohydrate antigens, respectively, located on glycoproteins . Proteins bound to these 
biotinylated lectins were then pulled down using streptavidin agarose (20 μl) as described 
previously [4]. Pulled-down proteins were then immunoblotted with EGFR and Her2.  
Similarly, lysates collected from wild-type control and C1GALT1-knockout PDAC 
cells were also also pulled down with biotinylated VVA and probed with MUC16 to detect 
Tn carbohydrate antigen variation on MUC16 in control and knockout cells. Further, 
Immunoprecipitation of control and C1GALT1 KO lysates were carried out with MUC4 
antibody using standard procedures. MUC4-pulled down lysates were then probed with 
carbohydrate antigens (Tn and STn) to detect carbohydrate antigen variation on MUC4 in 
control and knockout cells. 
 
14. Colony formation assay 
Colony formation assays were performed in scramble control and GALNT3-
knockdown cells using standard protocols [5]. Briefly 500 - 1000 cells were seeded in 6-
well plates and allowed to adhere overnight, following which media was changed to 1%, 
and the colony formation efficiencies of the cells were analyzed after 3 - 4 weeks by 
staining them with crystal violet (0.1%, w/v) in 20 nM 4-morpholinepropanesulfonic acid 
(Sigma Chemicals). 
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15. WST-1 assay 
Effect of GALNT3 knockdown on cell growth was assessed using WST-1 assay. 
For this assay, 1000 cells were plated onto 96-well plates and allowed to adhere overnight. 
On the next day, the media was changed to 1% DMEM, and WST-1 reagent was added 
to each well. Absorbance was measured at 450/630 nm 3 hours after WST-1 addition. 
Similarly, readings taken for another three consecutive days [6]. 
 
16. Wound healing assay 
Cell motility was evaluated in GALNT3-knockdown cells using a wound healing 
assay as described previously [7]. Additionally, wound healing assay was also conducted 
on control and C1GALT1 KO PDAC cells. Wound closure was evaluated in scramble 
control and GALNT3-knockdown cells using Image J software. 
 
17. Western and lectin blots 
Western blotting was performed using standard procedures and manufacturer’s 
protocols. Briefly, lysates were collected from PDAC cells 48 fours after plating. The 
above-listed lysates (40 μg) were probed for several oncogenic signaling proteins and 
EMT markers using antibodies listed in Table 2.3. After appropriate incubation of the 
secondary antibody, bands were visualized using enhanced chemiluminescence (ECL) 
(Thermo Scientific, Waltham, MA, USA). For lectin blotting, 2% BSA (Jackson 
Immunoresearch Labs) was used for blocking, and streptavidin HRP was applied to 
visualize bands using an ECL method [8]. 
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18. C1GALT1 enzyme activity assay  
Lysates collected from wild-type control cells and C1GALT1 KO cells were 
incubated with substrate GalNAcα-O-Benzyl and UDP-Gal. Identification of glycan 
structures synthesized by control and C1GALT1 knockout cells was carried out using LC-
MS and MS/MS analysis using well-described methods [9]. 
 
19. Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) 
Control and C1GALT1 knockout PDAC cells were incubated with media containing 
50 μM of the per-acetylated GalNAcα-OBn substrate for 72hrs. Following incubation, the 
culture supernatants from the GalNAcα-OBn treated PDAC cells were collected. FT-ICR 
MS was used to analyze glycosylated products synthesized on this substrate and secreted 
into culture media [9].  
 
20. RNA-seq analysis 
Total RNA was collected from control and C1GALT1 KO PDAC cells and submitted 
to RNA-Seq facility at UNMC. Gene expression analysis identified differentially 
upregulated and downregulated genes in control and C1GALT1 KO PDAC cells. (log fold 
change≥3). IPA analysis further identified the pathways affected in control and C1GALT1 
KO PDAC cells. 
 
21. Development of murine tumor cell lines and organoids 
Mouse tumors were finely minced and then processed for cell lines and organoids 
development. Cell lines were derived using standard procedures in a previously described 
method [6]. For organoid development, tissue was digested using special digestion buffer 
(collagenase).for 4 hrs. Following digestion, bigger tissue chunks were removed through 
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strainers and the flow-through was collected. After centrifugation, the cell pellet was 
washed twice and then mixed with Matrigel. A drop of Matrigel (around 30ul) containing 
tumor cells was then suspended in the center of 24-well plate. After the solidification of 
Matrigel, mouse-organoid specific media was added. The media was changed after every 
3-4 days and the organoids start appearing in 1-2 weeks [10]. 
 
22. Statistical Analysis 
For IHC, Student’s t-test was used to determine the statistical significance of 
variation in GALNT3 composite score among different disease groups. Similarly, for all the 
functional assays, Student’s t-test was used to determine statistical significance. A p-value 
of less than 0.05 was considered statistically significant.  All statistical analysis was 
performed using GraphPad Prism 7 software.
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Table 2.1: List of human primers used in the study 
 
 
Gene Primer sequence 
GALNT2 F-5’-AAG GAG AAG TCG GTG AAG CA-3’ 
R-5’-TTG AGC GTG AAC TTC CAC TG-3’ 
 
GALNT3 F-5’-AAA GCG TTG GTC AGC CTC TA-3’ 
R-5’-AAC GAG ACC TTG AGC AGC AT-3’ 
 
GALNT10  F-5’-ACA GCC AGG TAA TGG GTG A-3’ 
R-5’-GAA GAT GGG ATG GCT TTT CA-3’ 
 
GALNT11 F-5’-TGC TTA TCA GTG ACC GCT TG-3’ 
R-5’-ACA CTG TGC ACT GTC CGA AG-3’ 
 
GALNT12 F-5’-CAT CTT GCA GGA GGA TGG AT-3’ 
R-5’-CTG GCT CCA CAG TCT CCT TC-3’ 
 
GALNT13 F-5’-CAT CTA TCC GGA CTC CCA GA-3’ 
R-5’-TCG GTT CGG ATT TCT TTG TC-3’ 
 
GALNT14 F-5’-CTG AGA TGC ACA CTG CTG GT-3’ 
R-5’-CAT TTC ACC TTG GGC AAC TT-3’ 
 
CDH-1 F-5’-CGA TTC AAA GTG GGC ACA GAT GGT GT-3’ 
R-5’-CTG TAT TCA GCG TGA CTT TGG TGG AAA-3’ 
 
CDH-2 F-5’-CCT GAT ATA TGC CCA AGA CAA AGA GA-3’ 
R-5’-CAC TGT GCT TAC TGA ATT GTC TTG GGA-3’ 
 
VIM F-5’-GCA GCT CAA GGG CCA AGG CA-3’ 
R-5’-CCT GCA ATT TCT CCC GGA GGC G-3’ 
 
C1GALT1 F-5’-AAA TGG CCT CTA AAT CCT GGC-3’ 
R-5’-GAG TTT TAG CAA TTC CCT TCT C-3’ 
 
ST6GALNAC1 F-5’-GGA TAC AGT GGG AAT CTT GAG AC-3’ 
R-5’-GCC ATT TGC CAT CTT GAG AG-3’ 
 
ST6GALNAC2 F-5’-AAT GTC GGT GGA GTG TTC AG-3’ 
R-5’-CCT TGA ATC ACT TTA GCA TCT GG-3’ 
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Table 2.2: List of mouse primers used in the study 
 
Gene Primer sequence 
Kras  
(Genotyping) 
K006F-5’-CCT TTA CAA GCG CAC GCA GAC TGT AGA-3’ 
K005R-5’- AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC A-3’ 
 
p53  
(Genotyping) 
F-5’-CAC AAA AAC AGG TTA AAC CCA G-3’ 
F-5’-AGC ACA TAG GAG GCA GAG AC-3’ 
 
Pdx-1-Cre  
(Genotyping) 
F-5’-CTG GAC TAC ATC TTG AGT TGC -3’ 
R-5’-GGT GTA CGG TCA GTA AAT TTG -3’ 
 
C1galt1 
 
 
C1galt1 
(Genotyping) 
F-5′‐TGG GTT ATG ACA AGT CCT C-3′  
R-5′‐TCA TGT ATC CCT GCT TCA C-3′ 
 
F-5’-TGA CAG CCA GGA ATG GAA CTT G-3’ 
R-5’-GCC TCT TCT CGC AAC AAA ATA CTC-3’ 
 
Vimentin F-5'-CGG CTG CGA GAG AAA TTG C-3'  
R-5'-CCA CTT TCC GTT CAA GGT CAA G-3' 
 
Keratin-5 F-5′‐GAT GCC AGA AAC AAG CTG ACA GA-3′ 
R-5′‐TTC CCC ACT CAG CCT GCA CT-3′ 
 
Keratin-7 F-5′‐GCA GAG ATT GAC ACC TTG AAG AA-3′ 
R-5′‐TCC TGG TAC TCT CGA AGT TG-3′ 
 
Claudin-4 F-5′‐TCT GGG GAT GCT TCT CTC AGT-3′ 
R-5′‐AAG TCG CGG ATG ACG TTG TG-3′ 
 
Claudin-6 F-5′‐TGA CGC TCA TTC CTG TCT G-3′ 
R-5′‐AGA AGA GCA GGC GCA GCA TA-3′ 
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Table 2.3: List of antibodies used in the study 
 
Molecule Source Acquired from WB 
dilution 
IHC 
dilution 
IF 
dilution 
GALNT3 Rabbit Novus Biologicals 1:500 1:100 1:100 
CC49 Mouse (Sheer et al., 1988) 1:500   
SLex Mouse (Ogata et al., 1995) 1:500   
CA19.9 Mouse ATCC 1:1000   
Cyclin A Rabbit Santa Cruze 1:500   
E-cadherin Mouse Dr. Keith Johnson, 
UNMC 
1:500   
N-cadherin Mouse Dr. Keith Johnson, 
UNMC 
1:500   
Vimentin Rabbit Abcam 1:1000 1:400 1:400 
ZEB1 Rabbit Sigma 1:1000   
ZO-1 Rabbit Cell Signaling 1:1000   
Sox2 Rabbit Santa Cruze 1:1000   
pHer2 Rabbit Santa Cruze 1:1000   
Total Her2 Rabbit Santa Cruze ruze 1:1000   
pEGFR 
(Y1068) 
Rabbit Cell Signaling 1:1000   
pEGFR 
(S1046) 
Rabbit Santa Cruze 1:1000   
Total EGFR Rabbit Santa Cruze 1:500   
pHer3 Rabbit Cell Signaling 1:1000   
Total Her3 Rabbit Cell Signaling 1:1000   
C1GALT1 Mouse Abcam 1:1000   
C1GALT1 Rabbit Sigma  1:200  
Alpha-SMA Rabbit Abcam  1:400 1:400 
α4-Integrin Rabbit Cell Signaling 1:1000   
Β1-Integrin Rabbit Cell Signaling 1:1000   
pFAK-Y925 Rabbit Cell Signaling 1:1000   
pFAK-Y397 Rabbit Cell Signaling 1:1000   
Total FAK Rabbit Santa Cruze 1:1000   
MUC1 Mouse     
MUC4 (8G7) Mouse Generated in our 
lab 
1:1000   
MUC16 Mouse DAKO (M3520) 1:1000   
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CHAPTER 3 
Role of GALNT3 loss in pancreatic ductal adenocarcinoma 
 
The material covered in this chapter is the subject of one published research article: 
1. Chugh S, Meza J, Sheinin YM, Ponnusamy MP, Batra SK. Loss of N 
acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented 
aggressiveness and aberrant ErbB family glycosylation. Br J Cancer. 2016 Jun 14; 
114(12):1376-86. 
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1. Synopsis 
Aberrant glycosylation of several proteins underlie pancreatic ductal 
adenocarcinoma (PDAC) progression and metastasis. O-glycosylation is initiated by a 
family of enzymes known as polypeptide N-acetylgalactosaminyl transferases (GalNAc-
Ts/GALNTs). In this study, we investigated the role of the O-glycosyltransferase GALNT3 
in PDAC. Immunohistochemistry staining of GALNT3 was performed on normal, 
inflammatory and neoplastic pancreatic tissues. Several in vitro functional assays such as 
proliferation, colony formation, migration and tumour–endothelium adhesion assay were 
conducted in GALNT3 knockdown PDAC cells to investigate its role in disease 
aggressiveness. Expression of signalling molecules involved in growth and motility was 
evaluated using western blotting. Effect of GALNT3 knockdown on glycosylation was 
examined by lectin pull-down assay. N-acetylgalactosaminyl transferase 3 expression is 
significantly decreased in poorly differentiated PDAC cells and tissues as compared with 
well/moderately differentiated PDAC. Further, knockdown of GALNT3 resulted in 
increased expression of poorly differentiated PDAC markers, augmented growth, motility 
and tumour–endothelium adhesion. Pull-down assay revealed that O-glycans (Tn and T) 
on EGFR and Her2 were altered in PDAC cells, which was accompanied by their 
increased phosphorylation. Our study indicates that loss of GALNT3 occurs in poorly 
differentiated PDAC, which is associated with the increased and altered glycosylation of 
ErbB family proteins.
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2. Background and Rationale 
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive gastrointestinal 
malignancy with a very poor survival rate (i.e., around a 8% five-year survival rate) [1]. 
The lethal nature of this disease is due to its increased metastatic rate, which accounts 
for the extreme mortality rate among PDAC patients [2, 3]. In order to design and create 
much-needed targeted treatment modalities for PDAC, it is necessary to understand the 
gene signatures that contribute to its aggressiveness and high metastases. Several 
studies report the critical involvement of post-translational modifications on proteins during 
cancer development and progression [4, 5]. Further, aberrant changes in glycosylation 
patterns of proteins have been shown to underlie cancer growth and metastases [6, 7]. 
Proteins can undergo O- and N-glycosylation, which is determined by the amino acid 
getting modified by the glycan residues [8]. Mucin type O-glycosylation is the most 
common O-glycosylation that is initiated in the Golgi apparatus through a large family of 
20 enzymes, known as UDP-GalNAc:Polypeptide N-acetylgalactosaminyltransferases 
(i.e., GalNAc-Ts/GALNTs) [9]. GalNAcT enzymes catalyze the first step in mucin type O-
glycosylation, wherein these enzymes add an N-acetylgalactosamine sugar residue to the 
serine/threonine (Ser/Thr) residues on their specific substrates. This addition results in the 
formation of a Tn carbohydrate antigen [10], which can be either sialylated to form Sialyl-
Tn (STn) antigen, or it can be extended to several core carbohydrate structures [11].  
Despite of the functional homology, distinct substrate specificity has been reported 
for GalNAcTs [12]. For instance, during breast cancer, GalNAc-T6 has been shown to play 
a critical role in glycosylation of Mucin 1 (MUC1) [13]. Another study on hepatocellular 
carcinoma showed the significant involvement of GalNAc-T2 in glycosylation of the growth 
factor receptor EGFR [14]. GalNAc-T2 has also been shown to regulate EGFR 
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glycosylation and activity in oral squamous cell carcinoma. [15]. GalNAc-T3/ GALNT3 
enzyme is one of the members of the O-glycosylation-initiating GalNAc-T family, which 
has been shown to be highly expressed in oral squamous cell carcinomas and in ovarian 
cancer [16, 17]. Conversely, in lung adenocarcinoma and colorectal carcinoma, decreased 
expression of GALNT3 is reported, which is associated with a poor prognosis [18-20]. Few 
studies in pancreatic cancer have shown loss of expression of GALNT3 in poorly 
differentiated pancreatic cancer [21, 22]. However, the role of GALNT3 in pancreatic 
cancer progression and metastasis has not been explored much.  
The present study elucidates a novel role the loss of GALNT3 has in PDAC 
aggressiveness. The results from the present study evidence the association between the 
loss of O-glycosyltransferase GALNT3 and an altered glycosylation of ErbB receptors, 
accompanied by the increased phosphorylation of these growth factor receptors, leading 
to increased PDAC aggressiveness. Altogether, our study for the first time showed the 
pathobiological implications of loss of GALNT3 in poorly differentiated PDAC. 
 
3. Results 
A. Differential expression of GALNT3 in PDAC cells  
To investigate expression of the N-Acetylgalactosaminyl transferase 3, GALNT3, 
during PDAC, a panel of PDAC cell lines derived from well, moderate, and poorly 
differentiated carcinomas was used. GALNT3 protein expression was increased in well 
and moderately differentiated PDAC cells (CD18/HPAF, Capan-1, SW1990, Colo-357, 
BxPC3) as shown by western blot analysis, whereas poorly differentiated PDAC cells 
displayed no expression of GALNT3 (AsPC-1, Panc-1, MIA PaCa-2) (Figure 3.1A). To 
confirm these findings, immunofluorescence staining of GALNT3 expression was 
performed for certain PDAC cells with varied differentiation status (Supplementary 
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Figure 3.1a). In accordance with western blot data, immunofluorescence studies also 
demonstrated loss of GALNT3 in poorly differentiated PDAC cells. These results suggest 
that GALNT3 is differentially expressed in PDAC cells.  
 
B. Increased GALNT3 expression during PDAC progression from PanINs to 
well/moderately differentiated PDAC, but subsequent loss in poorly differentiated 
PDAC tissues 
To further evaluate the relationship between GALNT3 expression and disease 
progression, immunohistochemical (IHC) staining of GALNT3 was conducted on 
commercially availaible tissue arrays comprised of normal pancreatic tissues, samples 
procured from patients with chronic pancreatitis, pancreatic intraepithelial precursor 
lesions (PanINs), and PDAC (well differentiated, moderately differentiated and poorly 
differentiated). IHC staining was also performed on archived PDAC tissues procured via 
the Whipple procedure. Granular cytoplasmic pattern of staining was observed in tissues 
positive for GALNT3 expression. Normal pancreatic ducts were negative for GALNT3 
expression (weak staining in islets of Langerhans) (Figure 3.1C). Majority of chronic 
pancreatitis and PanINs samples showed negative staining, though weak staining was 
observed in few PanINs ducts (Table 3.1). Compared to PanIN lesions and chronic 
pancreatitis, the composite score for GALNT3 increased significantly (p<0.001) in the well 
and moderately differentiated PDAC samples. However, the composite score decreased 
significantly (p<0.05) in poorly differentiated cancer (Figure 3.1B). Overall, these results 
demonstrate that loss of GALNT3 expression occurs primarily during advanced and poorly 
differentiated PDAC, and not in moderately or well-differentiated PDAC (Representative 
picture-Figure 3.1C, Supplementary Figure 3.1c ). 
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C. GALNT3 knockdown and decreased expression of Tn carbohydrate antigen 
 To gain insight into the role of GALNT3 in PDAC progression, knockdown of 
GALNT3 was performed using specific shRNA in the following four different PDAC cell 
lines: CD18/HPAF, BxPC3, Capan-1, and T3M4. Knockdown was confirmed by western 
blot analysis and Real-Time PCR (Figure 3.2A, Supplementary Figure 3.1d). Since 
GALNT3 is the first enzyme in the O-glycosylation pathway and catalyzes the formation 
of Tn carbohydrate antigen, we next evaluated the expression of the Tn carbohydrate 
antigen in GALNT3-knockdown PDAC cells. VVA lectin blot demonstrated a slight 
decrease in expression of Tn carbohydrate antigen in GALNT3-knockdown PDAC cells 
(Figure 3.2B). 
 
D. Increased expression of poorly differentiated PDAC cell markers with loss of 
GALNT3 
 Considering that loss of GALNT3 expression occurred in poorly differentiated 
PDAC cells and tissues, the expression of poorly differentiated PDAC cell markers was 
examined in GALNT3-knockdown PDAC cells. However, no defined markers exist to 
characterize well, moderate, and poorly differentiated forms of PDAC. On the other hand, 
previous studies show that expression of the protein Sox2 increases in poorly 
differentiated PDAC cells [30, 31]. Another study showed loss of the carbohydrate antigen 
sialyl Lewis a (SLea /CA19.9) occurred in poorly differentiated PDAC [32]. In turn, the 
expression of Sox2 and SLea was evaluated in GALNT3-knockdown PDAC cells. Data 
showed increased expression of Sox2 and decreased expression of SLea in GALNT3-
knockdown PDAC cells (Figure 3.2C and 3.2D).  
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E. Increased PDAC cell growth and proliferation with GALNT3 knockdown   
In our results, loss of GALNT3 was observed in the poorly differentiated PDAC and 
therefore the effect of GALNT3 knockdown on disease aggressiveness was further 
examined in the study herein. Specifically, in vitro assays were used to examine the effect 
of GALNT3 knockdown on PDAC cell growth and proliferation. WST-1 assay results 
demonstrated significant increase in proliferation of GALNT3-knockdown CD18/HPAF 
cells (Figure 3.3A). GALNT3 knockdown also increased proliferation of Capan-1 PDAC 
cells (p-value <0.05, Supplementary Figure 3.2a). Further, increased numbers of 
colonies were observed in GALNT3-knockdown cells compared to scramble control cells 
(p-value <0.05, Figure 3.3B & 3.3C; Supplementary Figure. 3.2b). Additionally, 
increased proliferation and numbers of colonies in GALNT3-knockdown PC cells were 
also associated with increased expression of Cyclin-A (Figure 3.3D). Overall, these 
findings suggest that loss of GALNT3 expression leads to increased proliferation and 
growth of PDAC cells. 
 
F. Increased motility and endothelial cell adhesion of GALNT3 knockdown PDAC 
cells 
To determine the effect that GALNT3 has on cancer cell mobility, wound-healing 
assays were conducted for GALNT3-knockdown CD18/HPAF and BxPC3 PDAC cells. 
Notably, compared to scramble control cells, GALNT3 knockdown significantly increased 
the percentage of wound closure after 24 hours (p-value <0.05, Figure 3.4A). To further 
assess the effect that GALNT3 has on cancer cell mobility, the expression levels of 
epithelial mesenchymal transition (EMT) proteins involved in increased cell motility (e.g., 
E-cadherin, N-cadherin, vimentin and ZEB-1) were examined. Interestingly, increased 
expression was seen for mesenchymal markers (N-cadherin, vimentin and Zeb1), and 
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decreased expression was seen for epithelial marker (E-cadherin) in GALNT3-knockdown 
PDAC cells (Figure 3.4B; Supplementary Figure. 3.2c, e). Further, GALNT3-knockdown 
CD18/HPAF PDAC cells also showed EMT-like cell morphology (Figure 3.5A).  
Next, we evaluated the expression of the terminal carbohydrate epitope, sialylated 
Lewis x, SLex, for which a study by Kawarada et al. demonstrated its involvement in 
metastasis [33]. Data from our study revealed increased expression of SLex in GALNT3-
knockdown CD18/HPAF and BxPC3 PDAC cells (Figure 3.5B). Additionally, GALNT3-
knockdown CD18/HPAF and Capan-1 PDAC cells showed increased expression of 
sialylated Tn carbohydrate antigen (STn) (Supplementary Figure. 3.2d). Likewise, prior 
studies indicate that the negative charge imparted by sialic acid residues allows cancer 
cells to detach from each other, thus aiding in metastatic dissemination [34, 35]. Increases 
in SLex and STn carbohydrate antigens in GALNT3-knockdown PDAC cells suggest that 
there is not a complete abrogation of glycosylation in GALNT3-knockdown cells, which is 
potentially explained by the compensatory action of other GALNTs. For example, 
increased expressions of few GALNT genes were seen in GALNT3-knockdown cells (such 
as GALNT2, GALNT10 and GALNT11, GALNT12, GALNT13 and GALNT14) 
(Supplementary Figure. 3.3a, b). SLex carbohydrate antigen has been shown to facilitate 
cancer cells to cross the endothelium barrier through its interaction with E-selectin on 
endothelial cells, therefore to investigate the functional impact of increased SLex 
expression, we examined the adhesion of GALNT3 knockdown PDAC cells to endothelium 
cells [36, 37]. Interestingly, GALNT3 knockdown CD18/HPAF and BxPC3 cells showed 
significantly increased adhesion to endothelium cells as compared to scrambled control 
cells (Figure 3.5C). These results suggest that GALNT3 knockdown cells might have 
increased propensity to metastasize. 
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G. GALNT3 knockdown and altered expression of several oncogenic signaling 
proteins  
To gain insight into the mechanisms involved in increased aggressiveness of 
PDAC, we investigated the expression of ErbB proteins associated with increased tumor 
malignancy.  Increased phosphorylation of ErbB family of membrane receptors has been 
implicated in PDAC growth and motility [28, 38]. Data from the present study showed 
increased phosphorylation of ErbB family members, including EGFR, Her2, and Her3, in 
GALNT3-knockdown PDAC cells compared to scrambled control cells (Figure 3.6A).  
  
H. GALNT3 knockdown and altered glycosylation of EGFR and Her2 
To delineate the specific mechanisms by which increased phosphorylation of ErbB 
family members occurs the effect of GALNT3 knockdown on O-glycosylation modifications 
on these proteins was investigated. Previous studies evidence the involvement of altered 
O-glycosylation in regulating activation of EGFR [14, 15, 39]. Therefore to examine effect 
of GALNT3 knockdown on Tn and T carbohydrate antigens associated with EGFR and 
Her2, cell lysates from scramble control and GALNT3-knockdown cells were pulled down 
using biotinylated VVA (binds Tn carbohydrate antigen) and PNA lectins (binds T 
carbohydrate antigen) (Figure 3.6B). VVA and PNA pull down lysates were further probed 
with EGFR and Her2/Neu to examine Tn and T carbohydrate alterations on these 
receptors. Lectin-pull down assay demonstrated increased Tn and T carbohydrate 
antigens on EGFR and Her2 in GALNT3-knockdown CD18/HPAF and BxPC3 cells. 
(Figure 3.6B) Increased Tn and T carbohydrate antigens on these growth receptors in 
GALNT3 knockdown cells suggest the possible involvement of other GALNTs in EGFR 
glycosylation in aggressive PDAC. Interestingly, we observed upregulation of GALNT2, 
which has been shown to enhance the invasive potential of oral squamous cell carcinoma 
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by regulating EGFR glycosylation (Supplementary Figure. 3.3a, b) [15]. However, the 
role of GALNT2 in EGFR glycosylation in PDAC needs to be explored. 
 
4. Discussion 
Deregulated O-glycosylation of several proteins underlies cancer progression and 
metastasis. Furthermore, altered expression of glycosyltransferases leads to aberrant 
glycosylation of proteins, thus affecting their function. However, specific 
glycosyltransferases related to increased tumor aggressiveness have been unidentified. 
We identified that the O-glycosylation-initiating enzyme, GALNT3 is differentially 
expressed in PDAC. Using IHC staining, we found that GALNT3 expression decreased 
dramatically in poorly differentiated PDAC. Furthermore, we have analyzed some of the 
poorly differentiation markers in GALNT3 knockdown PDAC cells to prove the concept. 
However, there are no well-defined markers that can filter poorly differentiated PDAC from 
moderately or well-differentiated PDAC. On the other hand, recent studies on invasive and 
poorly differentiated PDAC showed increased expression of the transcription factor SOX2 
[30, 31]. In turn, we investigated whether loss of GALNT3 leads to increased expression 
of SOX2, thus serving as a marker for poorly differentiated PDAC cells. Interestingly, 
GALNT3-knockdown cells showed increased expression of SOX2. Further, we examined 
the expression of the carbohydrate antigen SLea in GALNT3-knockdown PDAC cells. 
SLea, also known as CA-19.9, is a clinically important prognostic marker for PDAC. Still, 
poorly differentiated PDAC cells have been shown to produce reduced amounts of CA-
19.9 as compared to well or moderately differentiated PDAC cells [32]. Expression of the 
carbohydrate antigen SLea was found to be decreased in GALNT3-knockdown PDAC cells 
as compared to scramble control cells. These results suggest that knockdown of GALNT3 
in PDAC cells might lead to the poorly differentiated state. Our findings are consistent with 
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previous studies also reporting loss of GALNT3 in other poorly differentiated cancers, 
including thyroid, gastric and colorectal carcinoma [20, 40, 41]. For instance, GALNT3 
expression in thyroid carcinoma is indicative of its differentiation status. Notably, poorly 
differentiated components of papillary thyroid carcinoma were found to be less positive for 
GALNT3 expression compared to well-differentiated components [41]. Based on these 
supporting studies, our results strongly suggest that GALNT3 is decreased in poorly 
differentiated PDAC. 
A 2011 study by Li et al. investigated the clinical significance of GALNT3 and 
GALNT6 in PDAC. Their results demonstrated negative staining for GALNT3 expression 
in poorly differentiated PDAC; however, expression pattern of GALNT3 in different stages 
of disease progression such as PanINs and chronic pancreatitis was not examined [22]. 
Further, the functional role of loss of GALNT3 expression in poorly differentiated 
pancreatic cancer has not been described in this study. Hence, the objective of our study 
was to study the impact of GALNT3 loss on pancreatic cancer pathogenesis. 
Several studies report associations between GALNT3 expression and 
clinicopathological features of cancers. For example, in lung adenocarcinoma, decreased 
expression of GALNT3 is associated with poorly differentiated tumors, poor survival, and 
lymph-node metastasis [18, 19]. Similarly, in the case of gastric and colorectal carcinoma, 
patients with decreased expression of GALNT3 showed poorer survival, whereas patients 
with strong GALNT3 expression had a good prognosis [20, 40]. Taken together, these 
studies suggest the loss of GALNT3 expression is associated with the more aggressive 
forms of cancer. In contrast to these studies, where loss of GALNT3 expression correlates 
with poor survival, a study in renal cell carcinoma shows that patients with positive 
GALNT3 cases have poor prognosis [42]. This suggests that the positive/negative 
correlation of GALNT3 expression with prognosis depends on specific type of tumor.  
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We next sought to determine the effect of GALNT3 knockdown on the 
aggressiveness of PDAC cells. Loss of GALNT3 in PDAC cells was accompanied by 
increased proliferation. Our findings contrast those from a 2011 study by Taniuchi et al., 
wherein data demonstrated that overexpression of GALNT3 leads to increased PDAC 
growth [43]. In our study, GALNT3-knockdown cells also displayed increased motility, 
accompanied by altered expression of EMT markers. Interestingly, our results corroborate 
previous findings by Kato et al. for hepatocellular carcinoma, wherein cells with increased 
metastatic potential were marked by decreased expression of GALNT3 [44]. Additionally, 
a 2014 study by Maupin et al., which focused on identifying glycogene alterations in PDAC 
EMT, also showed down-regulation of GALNT3 in mesenchymal-like PDAC cells [45]. 
Based on these supporting information, our results suggests that GALNT3 loss leads to 
aggressiveness of PDAC cells.  
Subsequently, we also found increased expression of SLex carbohydrate antigen 
in GALNT3-knockdown PDAC cells, which was associated with increased percentage 
adhesion of tumor cells to endothelial cells. Further investigations are necessary to identify 
the proteins carrying increased expression of SLex carbohydrate antigen in GALNT3 
knockdown PDAC cells These results indicate that GALNT3 knockdown cells have 
increased tendency for intravasation/extravasation, which is essential for metastasis. In 
accordance with results from the functional studies, we also investigated molecular 
alterations for several members of the ErbB family based on  previous study that showed 
the critical involvement of ErbB family members in PDAC growth and motility [46]. 
Likewise, we observed increased phosphorylation of EGFR, Her2, and Her3 in GALNT3-
knockdown PDAC cells. To further delineate the mechanism by which loss of a 
glycosyltransferase leads to increased phosphorylation of ErbB proteins and increased 
cancer aggressiveness, lectin pull-down assays were performed to identify glycan 
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alterations on EGFR and Her2. Recent studies highlight the significant involvement of O-
glycosylation modifications on EGFR in regulating EGFR-mediated oncogenic signaling. 
For instance, knockdown of GALNT2 in oral cancer has been shown to be associated with 
altered glycosylation and decreased activation of EGFR [15]. We identified that loss of 
GALNT3 in PDAC cells was associated with increased expression of Tn carbohydrate 
antigens on EGFR and Her2 proteins. Altered glycosylation on these members of the ErbB 
family of proteins could be a plausible mechanism for their increased activation. Increased 
expression of carbohydrate antigens on EGFR and Her2 with loss of GALNT3 provides a 
perspective about compensatory role of other members of GALNT family. The likelihood 
of such a switch in the expression/activity of GALNTs as disease progresses to an 
aggressive stage needs to be deciphered. 
Importantly, our study shows, for the first time, those O-glycan modifications exist 
on Her2. Prior studies have reported the existence of only N-glycans on Her2 [47]. Using 
the NetOGlyc 4.0 Server (http://www.cbs.dtu.dk/services/NetOGlyc/), which predicts 
mucin-type GalNAc O-glycosylation sites in mammalian protein sequences, we found few 
potential GalNAc O-glycosylation sites in the total Her2. This intriguing finding warrants 
more experimentation to investigate the exact sites of GalNAc O-glycosylation and the 
effect of altered glycosylation on the conformation of members of the ErbB family of 
proteins and their subsequent interaction with other signaling proteins.  
Overall, this study shows a novel role of loss of a glycosyltransferase, GALNT3, in 
PDAC, which is associated with altered glycosylation of ErbB receptors and increased 
aggressiveness of PDAC (Figure 3.7). Understanding the mechanism by which altered 
glycosylation brought by loss of GALNT3 leads to increased activation of EGFR and Her2, 
has the potential to pave the path for the development of novel and more effective 
therapeutic regimens. 
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Figure legends 
Figure 3.1 Differential expression of GALNT3 in PDAC cells and tissues: (A) Western 
blot analysis of GALNT3 expression in a panel of eight PDAC cell lines demonstrates loss 
of GALNT3 expression in poorly differentiated PDAC cells (W.D-well differentiated, M.D-
moderately differentiated, P.D-poorly differentiated). (B) Immunohistochemistry (IHC) 
staining performed on tissues representing chronic pancreatitis, PanIN lesions and 
different grades of PDAC revealed progressive increase of composite score of GALNT3 
from chronic pancreatitis and PanIN lesions to well differentiated PDAC, however the 
composite score is decreased in poorly differentiated PDAC. (C) Representative images 
of GALNT3 immunohistochemical staining in pancreatic cancer progression tissues-upper 
panel represents H&E staining of normal, chronic pancreatitis, PanIN, moderately and 
poorly differentiated pancreatic cancer tissues, wheras lower panel represents the 
corresponding GALNT3 staining in these tissues (figure magnification-400X, scale bar 
represents 50 μm, black arrows indicate ductal regions).
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Figure 3.2 Altered expression of poorly differentiated PDAC cell markers in GALNT3 
knockdown cells: (A) Stable knockdown of GALNT3 was carried out using GALNT3 
specific shRNA in four different PDAC cells-CD18/HPAF, BxPC3, Capan-1 and T3M4. 
Beta-actin was used as a loading control. (B) VVA lectin blot demonstrates decrease of 
Tn carbohydrate antigen in GALNT3 knockdown PDAC cells. (C) and D) Immunoblot 
analysis shows altered expression of differentiation markers with increased expression of 
Sox2 and decreased expression of SLea in GALNT3 knockdown PDAC cells.
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Figure 3.2 
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Figure 3.3 Effect of GALNT3 knockdown on growth and proliferation of PDAC cells: 
(A) Bar graph representing significant increase in proliferation of GALNT3 knockdown 
CD18/HPAF cells (p < 0.001) as demonstrated by WST-1 cell proliferation reagent. (B) 
Representative pictures of colony formation assay in CD18/HPAF and BxPC3 cells show 
significant increase in number of colonies (p < 0.001) in GALNT3 knockdown PDAC cells. 
(C) Increased expression of cell cycle regulatory protein Cyclin A in GALNT3 knockdown 
cells.
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Figure 3.3 
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Figure 3.4 Augmented motility of GALNT3-knockdown PDAC cells: (A) Increased 
percentage of wound-closure of GALNT3 knockdown cells after 24 hours. Marked areas 
show places of wound closure in scramble control and GALNT3-knockdown cells. Bar 
graphs represent a significant increase in the percentage of wound-closure in GALNT3-
knockdown CD18/HPAF and BxPC3 cells (p < 0.05 for CD18/HPAF, p < 0.001 for BxPC3 
PDAC cells). (B) Altered expression of EMT markers in GALNT3 knockdown PC cells. 
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Figure 3.4 
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Figure 3.5 Altered morphology and increased adhesion of GALNT3-knockdown 
cells to endothelium monolayer: (A) EMT-like morphological changes in GALNT3 
knockdown CD18/HPAF and BxPC3 PDAC cells. (B) Increased expression of metastatic 
SLex carbohydrate epitope in GALNT3-knockdown PDAC cells. (C) Bar graphs represent 
significant increase in percentage adhesion of GALNT3 knockdown cells to endothelial 
monolayer (p < 0.001). Representative immunofluorescent images showing increased 
adhesion of GALNT3 knockdown cells to endothelium monolayer as compared to 
scrambled control cells.
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Figure 3.5 
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Figure 3.6 Increased phosphorylation and altered glycosylation of members of the 
ErbB family of proteins in GALNT3-knockdown cells: (A) GALNT3 knockdown PDAC 
cells were associated with increase in phosphorylated forms of ErbB family of receptors 
such as EGFR, Her2, and Her3. (B) Lysates collected from scrambled control and 
GALNT3 knockdown cells were used for pull-down assays using biotin-conjugated VVA 
and PNA lectins. Immunoblotting of pulled down precipitates with biotinylated VVA and 
PNA lectins revealed effective pull-down of Tn and T carbohydrate antigens respectively. 
Further immunoblotting of pull-down lysates with anti-EGFR and Her2 antibodies 
demonstrated increase in Tn carbohydrate antigen association with EGFR and Her2 in 
GALNT3-knockdown CD18/HPAF and BxPC3 cells compared to scramble control cells. 
GALNT3 knockdown BxPC3 cells also displayed increased expression of T carbohydrate 
antigen on EGFR and Her2 as compared to scrambled control cells.
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Figure 3.6 
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Figure 3.7 Schematic illustration describing the impact of loss of GALNT3 on PDAC: 
Reduced expression of GALNT3 was observed in poorly differentiated PDAC tissues as 
compared to well-differentiated PDAC. Therefore, the functional impact of loss of GALNT3 
on PDAC cells was studied by stable knockdown of GALNT3 in PDAC cells. a) Knockdown 
of GALNT3 was associated with increased proliferation and motility. b) Further, GALNT3 
knockdown PDAC cells showed increased adhesion to endothelial cells. c) Increased 
aggressiveness of GALNT3 knockdown PDAC cells was accompanied by increased 
phosphorylation of ErbB receptors. Altered glycosylation was also observed on ErbB 
receptors, which suggests the possible involvement of O-glycans in regulating ErbB 
signaling. Overall, loss of GALNT3 leads to increased aggressiveness of PDAC cells. 
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Figure 3.7 
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Supplementary Figure legends 
Supplementary Figure 3.1: Knockdown of GALNT3 expression in PC cells: (a) 
Confocal analysis showed loss of GALNT3 expression in poorly differentiated Panc-1 PC 
cells. (b) IHC pictures demonstrating no staining in pancreatic cancer tissue with IgG 
control whereas GALNT3 antibody showed granular GALNT3 staining confirming the 
specificity of GALNT3 antibody. (c) Low power views of GALNT3 immunohistochemical 
staining in pancreatic cancer progression tissues-upper panel represents H&E staining of 
normal, chronic pancreatitis, PanIN, moderately and poorly differentiated pancreatic 
cancer tissues, whereas lower panel represents the corresponding GALNT3 staining in 
these tissues (figure magnification-100X, scale bar represents 2000 um). (d) Real time 
validation of GALNT3 knockdown in pancreatic cancer cells- (CD18/HPAF, BxPC3, 
Capan-1 and T3M4).
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Supplementary Figure 3.2: Aggressive phenotype of GALNT3 knockdown 
pancreatic cancer cells (a) Bar diagram showing increased proliferation of GALNT3 
knockdown Capan1 cells assayed by WST1 reagent. (b) Representative picture showing 
increased number of colonies in GALNT3 knockdown T3M4 cells. Bar plot depicts 
significant increase in number of colonies in GALNT3 knockdown T3M4 cells as compared 
to scramble control cells. (c) Western blot depicts decreased expression of E-cadherin 
and increased expression of N-cadherin in GALNT3 knockdown Capan-1 and T3M4 cells 
as compared to scramble control cells. (d) Increased expression of carbohydrate antigen 
STn in GALNT3-knockdown CD18/HPAF1 and Capan-1 cells. (e) Increased mRNA 
expression of N-cadherin and vimentin in GALNT3 knockdown cells, whereas expression 
of E-cadherin is decreased.
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Supplementary Figure 3.3: Compensatory increase of several GALNTs in GALNT3 
knockdown pancreatic cancer cells. Real time PCR analysis demonstrates 
upregulation of several GALNT genes in GALNT3-knockdown PC cells.
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Table 3.1: GALNT3 staining in normal, chronic pancreatitis, PanINs  
and PDAC. 
Group Numbe
r 
Staining intensity Mean 
composite 
score 
0 (negative) 1 
(weak) 
2 
(moder
ate) 
3 
(strong
) 
Normal 10 0 0 0 0 0 
Chronic pancreatitis 11 9 (81.8%) 1 
(9.01%) 
1(9.01
%) 
0 0.63 
PanINs (1/2/3) 29 22 (75.8%) 5 
(17.2%) 
1 (3.4%) 1  
(3.4%) 
0.79 
Well/moderate differentiated 
PDAC 
48 7 (14.5%) 16 
(33.3%) 
19 
(39.5%) 
6 
(12.5%) 
3.60 
Poor differentiated PDAC 26 15 (57.6%) 6 
(23.0%) 
2 
(7.69%) 
3 
(11.5%) 
1.76 
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CHAPTER 4 
Functional implications of knockout of C1GALT1 in pancreatic ductal 
adenocarcinoma
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1. Synopsis 
Aberrant expression/activity of O-glycosyltransferases during malignant conditions 
often result in impaired O-glycosylation and generation of truncated carbohydrate 
structures, also known as tumor-associated carbohydrate antigens (TACA) [1]. Abnormal 
expression of some of these truncated carbohydrate antigens such as Tn, STn is 
commonly observed in several malignancies including pancreatic ductal adenocarcinoma 
(PDAC) [2, 3]. Elevated expression of Tn has been attributed to inactive Core 1 β1, 3-
Galactosyltransferase (C1GALT1) [4, 5]. C1GALT1 catalyzes the second step of mucin-
type O-glycosylation by the addition of galactose to N-acetylgalactosamine (Tn) that forms 
Core 1 structure, which is usually elongated to several carbohydrate structures [6]. 
Functional C1GALT1 requires a molecular chaperone, Cosmc for its function [7]. Several 
studies have reported that loss of Cosmc in PDAC leads to inactive C1GALT1 and 
increased aggressiveness [8, 9]. However, the precise role of C1GALT1 mediated 
aberrant glycosylation in PDAC growth and metastasis remains unexplored. We sought to 
address the functional involvement of loss of C1GALT1 in PDAC aggressiveness by the 
generation of CRISPR/Cas9 C1GALT1 knockout (KO) PDAC cells. Knockout of C1GALT1 
in PDAC cells lead to truncated glycophenotype and increased aggressiveness of PDAC 
cells. C1GALT1 KO PDAC cells also showed increased tumor growth and metastasis in 
orthotopic implantation studies. Mechanistic studies identified that knockout of C1GALT1 
induced glycosylation changes on MUC16, which could drive increased tumorigenicity and 
metastasis possibly via increased expression of pAkt and vimentin.
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2. Background and Rationale 
Mucin-type O-glycosylation is the predominant form of O-glycosylation that involves a 
cascade of glycosyltransferases [10]. Sequential action of diverse glycosyltransferases 
that adds specific carbohydrate moieties results in the formation of mature O-glycans. 
Core-1 β-3 galactosyltransferase (C1GALT1) is one of the O-glycosyltransferases that 
catalyze the second step of O-glycosylation, wherein it adds galactose residue to first 
sugar, N-acetylgalactosamine/Tn, resulting in the formation of core-1/T carbohydrate 
structure [6]. Extension of core-1 carbohydrate structures by other glycosyltransferases 
results in core-2 carbohydrate structures. Functional C1GALT1 requires a molecular 
chaperone known as Cosmc (Core 1 β3-galactosyltransferase-specific molecular 
chaperone), which assists in its correct folding inside ER [7]. Dysfunctional Cosmc results 
in loss of activity of C1GALT1 and has been linked to several pathological states such as 
Tn syndrome, IgA nephropathy, and cancer [11]. Inactive C1GALT1 results in incomplete 
glycosylation and production of truncated Tn (GalNAcα-O-Ser/Thr) carbohydrate 
structure. Truncated Tn carbohydrate antigen can also be modified by sialylation by α-2, 
6-sialyltransferase, ST6GalNAc-1, to form STn [5]. Increased expression of both the 
truncated carbohydrate antigens, Tn and STn, has been observed in several malignancies 
including PDAC [2, 12].  
Prior studies in PDAC have indicated that loss of Cosmc (core 1 β3-Gal-T-specific 
molecular chaperone) via promoter hypermethylation leads to increased expression of 
truncated glycans and increased aggressiveness [8, 9]. However, loss of Cosmc could 
have other potential effects on PDAC cells. Hence, under cancerous conditions, it is 
important to understand the specific contribution of C1GALT1 mediated aberrant 
glycosylation in PDAC. Therefore, using CRISPR/Cas9 approach, we identified that 
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knockout of C1GALT1 caused aberrant glycosylation and increased tumorigenesis and 
metastasis. Mechanistic studies indicate that loss of C1GALT1 caused a remarkable 
increase in Tn on MUC16. Intriguingly, MUC16 is a membrane-bound mucin that 
originates de novo in PDAC and its expression increases progressively in PDAC [13, 14]. 
The mechanistic role of MUC16 in PDAC growth and metastasis has been well illustrated 
by our group and other studies [13-15]. Recent studies from our group have illustrated that 
MUC16 is one of the heavily glycosylated mucins and interacts with galectin-1 and 
galectin-3 [16]. Notably, mucin interaction to these lectins is facilitated by truncated 
carbohydrate antigens such as Tn and has been implicated in cancer metastasis [17]. 
Increased Tn on MUC16 might enhance its interaction with galectin or other carbohydrate 
binding proteins. Therefore, our studies conclude that loss of C1GALT1 in PDAC drives 
increase PDAC tumorigenesis and metastasis possibly via aberrant glycosylation on 
MUC16. 
 
3. Results  
A. Loss of expression of C1GALT1 in PDAC patient samples  
Real-time PCR analysis was performed using RNA isolated from PDAC tissues to 
examine the expressional variation of C1GALT1. PCR results demonstrated loss of 
C1GALT1 in the majority of PDAC samples examined (Figure 4.1A). Further, 
histochemical analysis of C1GALT1 expression was performed in several PDAC samples 
collected via Whipple procedure. Well and poorly differentiated regions of PDAC were 
scored independently for C1GALT1 expression. Trace to weak staining was observed in 
the majority of neoplastic ducts in well-differentiated PDAC tissues. Interestingly, most 
poorly differentiated PDAC areas stained negative for C1GALT1 (Figure 4.1B). The 
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C1GALT1 histochemical score was significantly reduced in poorly differentiated PDAC 
samples in comparison to well-differentiated PDAC tissues (Figure 4.1B). These results 
suggest differential expression of C1GALT1 in PDAC, where loss of C1GALT1 expression 
was observed in poorly differentiated PDAC. Our findings are in accordance with prior 
studies that have also reported a loss of inactive T-synthase (via Cosmc hypermethylation) 
in some PDAC samples [9].  
 
B. Decreased expression of C1GALT1 with oncogenic transformation of normal 
pancreatic epithelial cells  
In order to determine whether oncogenic transformation affects C1GALT1 
expression, lysates from well characterized immortalized human nestin-positive normal 
pancreatic epithelial cells (HPNE) and fully transformed HPNE cells (hTERT-HPNE-
E6/E7/st-KRAS(G12D)) were probed for C1GALT1 using western blotting.[18]. Oncogenic 
transformation of HPNE cells was associated with decreased expression of C1GALT1 
(Figure 4.2). 
 
D. Truncated glycan signature with CRISPR/Cas9 KO of C1GALT1 in PDAC cells 
To explore the functional role of C1GALT1, knockout of C1GALT1 was carried in 
authenticated PDAC cells (T3M4, CD18/HPAF, and SW1990 cells) using CRISPR/Cas9- 
based genome editing. Western blotting demonstrated complete knockout of C1GALT1 in 
CRISPR/Cas9 KO clones as compared to untransfected control cells (Figure 4.3A). 
Further, Sanger sequencing of T3M4 knockout cells revealed genetic insertion as 
compared to the wild-type control cells (Figure 4.3B).  
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Deletion of C1GALT1 in the knockout cells was further confirmed by C1GALT1 
enzymatic assay using benzyl-α-GalNAc substrate (Figure 4.4). Addition of galactose to 
this substrate (brought by C1GALT1 activity) was completely abolished in KO clones as 
compared to control cells. Formation of core-1 glycan structures and extended core-1 
structures was seen in wild-type control cells. However, KO clones completely lack these 
structures. Altogether, these results indicate effective knockout of C1GALT1 expression 
and activity in KO clones as compared to wild-type controls.  
We next evaluated the glycosylation profile of C1GALT1 KO PDAC cells. We 
observed increased expression of Tn and STn in all the KO clones as compared to wild –
type control (Figure 4.5A). VVA fluorescein staining further confirmed increased 
expression of Tn and STn carbohydrate antigen (Figure 4.5B). Comprehensive analysis 
of the effect of C1GALT1 on O-glycan biosynthetic pathways was further performed using 
Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS). Here, we 
looked for secretory O-glycans in the culture supernatants collected from the control and 
KO clones. Several O-glycan peaks were observed in wild-type control cells, whereas KO 
cells completely lack these peaks (Figure 4.6).   
 
E. Increase of ST6GalNAc-2 in C1GALT1 KO PDAC cells 
Since ST6GalNAc-1 has been shown to catalyze the production of STn, we 
checked if increased production of STn is linked to increased expression of ST6GalNAc-
1 (ST6 N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 1). Surprisingly, we observed 
decreased expression of ST6GalNAc-1 in KO clones as compared to wild-type control 
cells (Figure 4.7A). Studies have demonstrated that ST6GalNAc-II, another 
sialyltransferase, can also catalyze STn biosynthesis. We identified marginal increase of 
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ST6GalNAc-II in KO clones as compared to control cells (Figure 4.7B). ST6GalNAc-II 
might facilitate STn biosynthesis in absence of ST6GalNAc-I. However, this needs to be 
tested.  
 
F. Loss of C1GALT1 resulted in increased migration of PDAC cells  
Knockout of C1GALT1 induced formation of cellular protrusions such as 
lamellipodia, filopodia, and microspikes as demonstrated by F-actin staining (Figure 4.8). 
Since the formation of these dynamic cytoskeletal structures directs cancer cell migration, 
the effect of C1GALT1 knockout on cancer cell migration was examined using wound-
healing assay (Figure 4.9). The wound-healing assay showed a significant increase in 
cell motility of C1GALT1 KO PDAC cells.  
 
C. Decreased expression of C1GALT1 in highly migratory sublines of PDAC cells 
Since knockout of C1GALT1 resulted in increased migration, we next examined if 
expression of C1GALT1 is modulated in highly migratory PDAC cells. Therefore, we 
developed an in vitro model of migration that comprises less to more migratory PDAC 
sublines. Serial migration assay was conducted to develop highly migratory sublines of 
T3M4, BxPC-3 and Colo-357 (Figure 4.10A). Briefly, the parental cells (P) were seeded 
in migration chambers and cells that had migrated after 24 hrs were collected by scraping 
them with sterile cotton swabs, which were then immersed in media to develop the 
migratory subline (M1). Subsequently, the M2 subline was developed from the M1 subline 
by carrying out its migration for 24 hrs. Series of migration assays with a gradual decrease 
of migration time (12hr, 6hr, and 3hr) resulted in the development of the highly migratory 
M3, M4 and M5 sublines. Migration potential of parental and these highly migratory T3M4 
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PDAC sublines was assessed using migration assay. Migration assay demonstrated 
increased migration of migratory sublines as compared to parental cells (Figure 4.10B). 
Further, altered morphology (increased presence of cellular protrusions) was seen in 
these migratory sublines as compared to parental cells (Figure 4.10B).   
Expression of C1GALT1 was examined in the parental and the migratory sublines 
derived from T3M4, BxPC-3 and Colo-357 using western blotting. Expression of C1GALT1 
was decreased in highly migratory M4 and M5 sublines as compared to parental cells in 
T3M4 and BxPC3 migratory model (Figure 4.11A). C1GALT1 expression was also 
decreased in highly migratory Colo-M1 and Colo-M2 cells as compared to parental cells 
(Figure 4.11B). These findings further suggests that loss of C1GALT1 expression is 
associated with increased migration. 
 
G. In vivo studies using C1GALT1 KO cells showed increased tumorigenicity and 
metastasis 
 We next sought to assess the impact of C1GALT1 knockout on tumor growth and 
metastasis using orthotopic implantation mouse model, wherein wild-type and C1GALT1 
KO T3M4 PDAC cells were implanted into the pancreas of nude mice. Mice were 
euthanized 4 weeks after orthotopic implantation and the formation of tumors and 
metastatic lesions was examined. Two independent orthotopic implantation studies were 
performed using two different C1GALT1 clones to explore the involvement of C1GALT1 
KO clones on tumorigenicity and metastasis. Our first study utilized GFP and luciferase 
labeled wild-type and C1GALT1 KO clone-3 PDAC cells. Orthotopic results revealed a 
significant increase in tumor weight and increased metastasis to distant organs such as 
liver, lung, diaphragm and peritoneum (Figure 4.12 A, B). 
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 To further validate our findings, we used wild-type and C1GALT1 KO clone-4. 
Orthotopic studies using this clone also demonstrated significant increases in tumor 
weight and increased metastasis (Figure 4.13 A, B). Altogether, in vivo orthotopic studies 
using wild-type and C1GALT1 KO clones indicates that KO of C1GALT1 contributes to 
increased tumorigenicity and metastasis of PDAC cells. 
 
I. Differential glycosylation of MUC16 in C1GALT1KO PDAC cells 
To delineate the molecular mediators that confer increased PDAC aggressiveness 
in C1GALT1 KO PDAC cells, we examined the expression of mucins. Mucins are the 
preferential substrates for C1GALT1 owing to the presence of central domain that contains 
PTS (proline, serine, and threonine) rich repeats. Some of the mucins such as MUC1, 
MUC4, and MUC16, are also widely recognized to play an important role in PDAC growth 
and metastasis.[19] We investigated the expression of these aforementioned mucins 
using western blotting. Western blot results demonstrate a remarkable shift in molecular 
weight of MUC16 (Figure 4.14). The MUC16 band was seen at lower molecular weight 
position in C1GALT1 KO cells as compared to wild-type cells. However, such a shift was 
not observed for MUC1 and MUC4.  
 Since glycosylation also contributes to the molecular weight of protein substrates, 
we investigated if the observed decrease in molecular weight of MUC16 is due to loss of 
extended glycan structures on MUC16. As C1GALT1 deficiency leads to loss of extended 
glycan structures with subsequent increase of truncated glycan structures such as Tn and 
STn, the presence of Tn glycan on MUC16 was determined using VVA (binds Tn) pull 
down assay. Lectin pull down assay using T3M4 wild-type and C1GALT1 KO lysates 
showed increased expression of Tn on MUC16 in C1GALT1 KO lysates as compared to 
110 
 
 
 
wild-type cells (Figure 4.15 A). These results suggest that loss of C1GALT1 leads to 
altered glycosylation on MUC16 with increased expression of Tn carbohydrate antigen 
 We further tested glycosylation alterations on MUC16 in C1GALT1 KO PDAC cells 
using enzymatic approaches, wherein we utilized glycosidases such as PNGase-F and α-
2,3,6,8 neuraminidase (Figure 4.15 B). PNGase-F specifically excise N-glycans whereas, 
α-2,3,6,8 neuraminidase catalyzes the removal of all terminal and branched sialic acid 
residues. Lysates from wild-type and KO cells were treated with these enzymes and were 
probed with MUC16. PNGase-F treatment in wild-type and C1GALT1 KO lysates caused 
molecular shifts in bands that correspond to N-glycosylated MUC16. Similar kind of shifts 
was seen in wild-type and C1GALT1 KO lysates, suggesting that KO of C1GALT1 didn’t 
alter N-glycosylation of MUC16. On the other hand, cleavage with neuraminidase resulted 
in increased intensity of MUC16 band in both wild-type and C1GALT1 KO lysates. This 
can possibly be explained due to increased exposure of epitopes after the release of sialic 
acid residues that caused increased binding of the MUC16 antibody (raised against the 
tandem repeat region of MUC16 that represents most of the O-glycosylated region). 
Hence, increased intensity regions represent a sialylated region of MUC16. Interestingly, 
the increase in intensity was seen at a lower position in C1GALT1 KO lysates as compared 
to wild-type lysates. This further suggests that the shift in molecular weight of MUC16 is 
caused by a decrease in O-glycosylation. 
 The aforementioned results explain that C1GALT1 KO caused a shift in molecular 
weight of MUC16 due to altered glycosylation. We also pulled down MUC4 from lysates 
collected from wild-type and C1GALT1 KO T3M4 cells and probed them with Tn and STn. 
Interestingly, pulled-down MUC4 from both wild-type and C1GALT1 KO lysates didn’t 
show the presence of truncated glycans (Figure 4.16). This suggests that MUC4 in T3M4 
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PDAC might not possess truncated glycans. This can possibly explain why we didn’t 
observe any shift in molecular weight of MUC4 in C1GALT1 KO cells. However, this 
doesn’t indicate that MUC4 is not glycosylated and predominant glycotopes (could be 
core-3/4 carbohydrate structures) present on MUC4 in T3M4 PDAC cells need to be 
explored. 
 
H. Differential upregulation of tumorigenic and metastatic pathways in C1GALT1 
KO PDAC cells  
To identify how altered glycosylation impacts tumor growth and metastasis, RNA-
Seq analysis was conducted on control and C1GALT1 KO PDAC samples that identified 
pivotal molecular pathways involved in increased aggressiveness of C1GALT1 KO PDAC 
cells. RNA-Seq results revealed differentially expressed genes (log 2 fold 
upregulated/downregulated) in the C1GALT1 KO T3M4 cells in comparison with the wild-
type (Figure 4.17). Significant upregulations of genes involved in migration and tumor 
growth was observed in C1GALT1 KO PDAC cells as compared to control cells (Figure 
4.17). IPA analysis of these differentially expressed genes identified upregulation of pAkt 
pathway in KO cells as compared to control cells (Figure 4.18).  
Further, using western blotting, we validated increased activation of oncogenic and 
migratory signaling pathways (as predicted by RNA-seq). We observed increased 
expression of phosphorylated forms of ErbB signaling proteins such as EGFR and Her2 
in knockout clones as compared to wild-type cells. However, the total levels of these 
signaling proteins remain unchanged (Figure 4.19A). We also observed increased 
expression of α-4 integrin in C1GALT1 KO Clones. All of these signaling proteins have 
been shown to play an important role in PDAC growth and metastasis. Increased 
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activation of Akt (downstream effector of ErbB signaling) and FAK-Y925 (downstream 
effectors of integrin signaling) was also observed (Figure 4.19A, B). Furthermore, 
increased activation of these signaling proteins has been associated with altered 
expression of EMT markers. Remarkably, increased expression of mesenchymal marker 
vimentin was seen in C1GALT1 KO PDAC cells, whereas expression of epithelial marker 
ZO-1 was decreased in C1GALT1 KO PDAC cells.  
 
J. Regulation of C1GALT1 by cytokines in the tumor microenvironment 
We next wanted to understand if the C1GALT1 expression is modulated during 
disease progression as a subset of patients expressed C1GALT1. Since secretory factors 
in the tumor microenvironment have been shown to regulate glycosylation, we examined 
the impact of cytokines in the tumor microenvironment on C1GALT1 expression. Suzuki 
et al. demonstrated that IL-4 and IL-6 cytokines decrease C1GALT1 expression, which 
results in altered IgA1 glycosylation that is implicated in IgA nephropathy. We treated 
T3M4 PDAC cells with several inflammatory cytokines such as IFN-γ, TNF-α and different 
doses of IL-4 and IL-6 (25 ng/ml, 50 ng/ml, and 100 ng/ml) (Figure 4.20). IFN-γ and TNF-
α caused a slight increase of C1GALT1 expression. A lower dose of IL-4 lead to slight 
increase of C1GALT1 expression, whereas higher doses of IL-4 resulted in decreased 
expression of C1GALT1. Interestingly, treatment with IL-6 resulted in a dose-dependent 
decrease of C1GALT1 expression, wherein maximum effect was observed at 100ng/ml. 
 
4. Discussion 
Altered expression/activity of O-glycosyltransferases has been observed in several 
malignancies including PDAC [20]. This results in altered glycophenotype that has been 
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implicated in tumor growth and metastasis [21]. Not much has been studied about O-
glycosyltransferases that are linked with increased PDAC aggressiveness. We observed 
that O-glycosyltransferase, C1GALT1 is not expressed by some PDAC patients. Further, 
the C1GALT1 expression is dramatically decreased in poorly differentiated PDAC as 
compared to well-differentiated PDAC. Our results corroborate with previous studies 
focused on Cosmc that have also indicated loss of activity of O-glycosyltransferase, 
C1GALT1, in PDAC. Radhakrishnan et al. have identified hypermethylation of the 
promoter region of the C1GALT1 chaperone, Cosmc, in PDAC samples, which was 
associated with loss of C1GALT1 expression and subsequent increase of truncated O-
glycans [9].  
Apart from patient samples, we also observed decreased expression of C1GALT1 in 
oncogenic transformed HPNE cells (HPNE-E6/E7/St/KRAS) [18]. These results suggest 
that loss of C1GALT1 might be associated with increased aggressiveness of PDAC cells. 
Hence, to explore the functional impact of loss of C1GALT1 on PDAC aggressiveness, 
CRISPR/Cas9-mediated C1GALT1 knockout was carried out in PDAC cells. Using a 
C1GALT1 enzymatic assay, we found that KO cells does not synthesize core-1/extended 
core-1 structures. Since C1GALT1 catalyzes the elongation of Tn carbohydrate antigen to 
T carbohydrate/core-1 antigen in mucin-type O-glycosylation, we investigated if loss of 
C1GALT1 results in incomplete O-glycosylation. Lectin blotting and immunofluorescence 
revealed increased expression of Tn carbohydrate antigen. We also noticed increased 
expression of STn carbohydrate antigen. These results suggest that abrogation of 
C1GALT1 activity leads to increased expression of Tn and STn carbohydrate structures, 
which are commonly observed in cancer and have been implicated in increased growth 
and motility [2, 12, 22]. For instance, increased expression of STn in gastric cancer cells 
was associated with increased intraperitoneal metastasis [23]. Further, we noticed that 
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C1GALT1 KO PDAC cells have altered morphology with increased presence of 
cytoplasmic protrusions such as lamellipodia, fliopodia and microspikes. Organization of 
actin filaments into these cytoplasmic protrusions allows cancer cells to migrate, invade 
and hence successfully metastasize [24, 25]. We found increased migration of C1GALT1 
KO cells as compared to control cells. In addition to this, we also observed decreased 
expression of C1GALT1 in highly migratory PDAC cells as compared to less migratory 
PDAC cells. Furthermore, orthotopic studies in nude mice demonstrated increased 
tumorigenicity and metastasis with knockout of C1GALT1. Our data are strongly supported 
by previous studies that have also linked altered glycosylation with increased metastasis 
[21, 26].  
Given that knockout of C1GALT1 induced aberrant glycosylation, it is important to 
identify aberrantly glycosylated molecular substrates that drive the observed increase in 
PDAC aggressiveness. We focused on mucins, which are heavily glycosylated and play 
an important role in PDAC growth and metastasis [19]. Elevated expression of membrane 
and secretory mucins is one of the key features of PDAC. For instance, de novo 
expression of MUC4 and MUC16 has been observed in PDAC, wherein it leads to 
increased growth and metastasis [13, 14, 31]. Recently, using CRISPR/Cas9 knockout of 
MUC16, our group has recently shown the essential role of MUC16 in PDAC metastasis 
through activation of FAK signaling [16]. Further, the study also indicated MUC16 as one 
of the heavily glycosylated mucins, as knockout of MUC16 was associated with decreased 
expression of Tn and T carbohydrate antigens [16]. Using lectin-pull down and enzymatic 
assays, we found that knockout of C1GALT1 dramatically altered MUC16 glycosylation. 
In particular, increased expression of Tn was observed on MUC16.  
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RNA-seq analysis of C1GALT1 KO cells provided molecular insights into the 
mechanism involved in increased tumorigenicity and metastasis of C1GALT1 KO PDAC 
cells. Significant increase in migratory and tumorigenic genes was observed in KO PDAC 
cells as compared to parental cells. IPA analysis of RNA-seq data identified upregulation 
of PI3K/Akt pathway that has been implicated in PDAC growth and metastasis [30]. 
Consistent with these findings, we also observed activation of oncogenic signaling 
proteins (pEGFR, pHer2, pAkt) and altered expression of EMT markers (pFAK-Y925, ɑ4 
integrin, Vimentin and ZO-1) in C1GALT1 KO PDAC cells. Studies from several other 
groups and our group have illustrated the pivotal role of these signaling pathways in 
increased PDAC growth and metastasis [28, 29]. We observed a remarkable increase of 
vimentin expression in C1GALT1 KO cells, which might explain increased migration of 
C1GALT1 KO cells.  Expression of this intermediate filament protein is upregulated during 
EMT and renders cancer cells with increased motility [27]. We speculate that increased 
tumorigenicity and metastasis could be attributed to aberrant glycosylation of MUC16, 
which caused increased activation of growth and metastatic pathways, possibly via 
increased interaction with growth receptors/signaling proteins. We have recently shown 
that MUC16 regulates PI3K/Akt signaling [16]. pAkt has been shown to phosphorylate 
vimentin that prevents its proteolytic degradation and hence mediates increase cancer cell 
migration [32]. However, the direct involvement of aberrantly glycosylated MUC16 in 
activation of this putative signaling pathway needs to be explored. 
Altogether, our study has established that knockout of C1GALT1 in PDAC leads to 
increased tumorigenicity and metastasis possibly via altered glycosylation on MUC16 that 
can potentially activate oncogenic pAkt signaling, resulting in increased expression of 
vimentin and hence increased growth and metastasis.
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Figure legends 
Figure 4.1 Loss of expression of C1GALT1 in PDAC: (A) PCR analysis of C1GALT1 in 
PDAC patients demonstrates loss of C1GALT1 in the majority of PDAC patients 
examined. (B) Top Panel: Scatter dot plot demonstrating significant decrease of 
C1GALT1 in poorly differentiated PDAC as compared to well differentiated PDAC. Bottom 
panel: Representative immunohistochemical pictures showing decreased C1GALT1 
staining in poorly-differentiated PDAC as compared to well-differentiated. Weak C1GALT1 
staining was also observed in normal pancreas. All the pictures were taken at 40X 
magnification. **P<0.005; by Mann Whitney test.
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Figure 4.1 
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Figure 4.2 Decreased C1GALT1 expression in oncogenic transformed HPNE cells: 
Western blotting demonstrates decreased expression of C1GALT1 in oncogenic 
transformed HPNE cells (hTERT -HPNE-E6/E7/St/KRAS) as compared to untransformed 
HPNE (hTERT –HPNE) cells. 
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Figure 4.2 
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Figure 4.3 CRISPR/Cas9 Knockout of C1GALT1 in PDAC cells: (A) Western blotting 
demonstrates complete knockout of C1GALT1 in T3M4 and CD18/HPAF PDAC cells (B) 
Sanger sequencing reveals presence of insertion of adenosine nucleotide in guide RNA 
targeting region of T3M4 knockout PDAC cells as compared to wild type control cells.
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Figure 4.3 
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Figure 4.4 Characterization of T3M4 knockouts: (A) Core1 β1,3GalT enzyme activity 
was assayed by mixing cell lysates from wild-type T3M4 cells and knockouts with 
substrate GalNAcα-O-Benzyl in the presence of UDP-Gal. Relative abundance of original 
substrate (top panel) and product (bottom panel) was quantified based on the area under 
the curve of the MS1 peak for the corresponding molecule. All structures were validated 
using MS/MS analysis. (B) Core 1 synthase enzyme activity in wild-type T3M4 cells 
(control) and three different knockouts (Clone 2-4). Absence of Galβ1,3GalNAcα-OBn 
product in T3M4-KO clones is indicated by asterisk. (C) Per-acetylated GalNAcα-OBn was 
fed to wild-type and C1GALT1 KO cells. Products collected from supernatant were 
assayed using LC-MS, with structure validation being performed using MS/MS analysis 
and existing knowledge of biochemistry. All glycans are depicted using Symbol 
Nomenclature for Glycans. (D) Nano-LC separation of various glycosides secreted from 
wild-type T3M4 cells. Knockout cells lacking Core1 β1,3GalT do not form any of these 
products.  
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Figure 4.4 
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Figure 4.5 Aberrant glycosylation of C1GALT1 KO PDAC cells: (A) Upper panel: 
Lectin blotting demonstrates increased expression of Tn carbohydrate antigen in 
C1GALT1 KO clones as compared to control cells. Lower panel: Western blotting 
demonstrates increased expression of STn carbohydrate antigen in C1GALT1 KO clones 
as compared to control cells. (B) VVA Fluorescein staining revealed increased expression 
of Tn carbohydrate antigen in C1GALT1 KO clones as compared to control cells.
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Figure 4.5 
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Figure 4.6 Mass spectrometry analysis of O-glycan biosynthesis pathway in T3M4 
cells: A. T3M4 cells were cultured with 50 μM per-acetylated GalNAcα-OBn for 72h. 
Glycosylated products synthesized on this substrate and secreted into culture media were 
analyzed using Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR 
MS). A number of glycan peaks were observed in the wild-type control (panel ii, top) but 
not C1GALT1 knockout (panel ii, bottom) cells. Measured and theoretical monoisotopic 
masses are provided along with isotopic peak distribution for all carbohydrates. B. 
Potential biosynthetic pathway in wild-type T3M4 cells is illustrated based on knowledge 
of biochemistry and MS data.
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Figure 4.6 
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Figure 4.7 Altered expression of sialyltransferases in C1GALT1 KO PDAC cells: (A) 
RT-PCR analysis demonstrates a significant decrease in ST6GALNAC1 expression in 
C1GALT1 KO T3M4 PDAC cells as compared to control cells. (B) RT-PCR analysis 
demonstrates a significant increase in ST6GALNAC2 expression in C1GALT1 KO T3M4 
PDAC cells as compared to control cells. *P<0.05, **P<0.005; by unpaired two-sided 
Student’s t-test.
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Figure 4.7 
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Figure 4.8 Altered morphology of C1GALT1 KO PDAC cells: F-actin staining 
demonstrates altered morphology with increased presence of cellular protrusions (marked 
by arrows) in C1GALT1 KO T3M4 PDAC cells as compared to control cells.
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Figure 4.8 
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Figure 4.9 Increased migration of C1GALT1 KO PDAC cells: (A) Representative 
pictures from wound-healing assay after 24 hrs. showing increased migration of C1GALT1 
KO T3M4 PDAC cells as compared to control cells (B) Quantification of wound-healing 
assay shows significant increase of wound closure in C1GALT1 KO T3M4 PDAC clones 
as compared to control cells. *P<0.05, **P<0.005; by unpaired two-sided Student’s t-test.
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Figure 4.9 
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Figure 4.10 Development of migratory model of PDAC: (A) Migration assay was 
conducted using parental PDAC cells for 24hrs and the migratory subline M1 was 
developed using cells that have migrated. Further, M1 subline PDAC cells was seeded in 
migration chamber to develop M2 subline. Similarly, series of migration assays with 
migratory sublines with progressive decrease in incubation time lead to the development 
of highly migratory M3, M4 and M5 sublines. (B) Representative picture from migration 
assay demonstrating high migration of migratory sublines as compared to parental cells. 
Further, actin staining demonstrates altered morphology of migratory sublines as 
compared to parental cells.  
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Figure 4.10 
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Figure 4.11 Decreased expression of C1GALT1 in highly migratory PDAC sublines: 
A. Left Panel: Western blotting demonstrating decreased expression of C1GALT1 in 
highly migratory T3M4-M4 and T3M4-M5 PDAC cells as compared to parental cells. 
Further, all the migratory sublines showed increased expression of N-cadherin and 
vimentin as compared to parental cells. Right Panel: Western blotting demonstrating 
decreased expression of C1GALT1 in highly migratory BxPC3-M4 and BxPC3-M5 PDAC 
cells in comparison with parental cells. B. C1GALT1 immunoblotting demonstrating 
decreased expression of C1GALT1 in highly migratory Colo-M1 and Colo-M2 sublines as 
compared to parental cells. Further, these migratory sublines showed increased 
expression of vimentin as compared to parental cells. 
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Figure 4.11 
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Figure 4.12 Impact of GFP and luciferase labelled C1GALT1 KO clone-3 on tumor 
growth and metastasis: (A) Left panel: Orthotopic implanation of GFP and luciferase 
labelled control and KO-clone 3 T3M4 PDAC cells in nude mice revealed significant 
increase in tumor weights with knockout of C1GALT1. Right panel: Representative 
pictures of bioluminescence imaging and pancreatic tumors from control and C1GALT1 
KO mice cohort. (B) Left panel: Bar diagram showing significant increase in diaphragm 
metastasis with orthotopic implantation of C1GALT1 KO-3 as compared to control cells. 
Right panel: Representative pictures of GFP positivity in metastatic lesions to kidney, 
spleen, ovary, diaphragm and testis. Error bars represent mean ± s.e.m ,*P<0.05 by Mann 
Whitney test.
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Figure 4.13 Impact of C1GALT1 KO clone-4 on tumor growth and metastasis: (A) 
Orthotopic implantation of control and KO-clone 4 T3M4 PDAC cells in nude mice revealed 
significant increase in tumor weights with knockout of C1GALT1. (B) Bar diagram showing 
significant increase in kidney metastasis with orthotopic implantation of C1GALT1 KO-4 
as compared to control cells. Error bars represent mean ± s.e.m *P<0.05 by Mann Whitney 
test.
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Figure 4.13 
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Figure 4.14 Expression of Mucins in C1GALT1 KO PDAC cells: Western blotting 
demonstrates molecular shift in the MUC16 band in C1GALT1 KO PDAC cells as 
compared to control cells. Further, the expression of MUC4 and MUC1 is dramatically 
reduced in C1GALT1 KO PDAC cells as compared to control cells (indicated by arrows).
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Figure 4.14 
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Figure 4.15 Aberrant MUC16 glycosylation in C1GALT1 KO PDAC cells: (A) Upper 
Panel: Lectin blotting demonstrates effective pull-down of Tn carbohydrate antigen in 
control and C1GALT1 KO T3M4 cells by VVA pull down assay.  Bottom Panel: 
Immunoblotting of VVA pulled down control and C1GALT1 KO lysates with MUC16 
demonstrates significant increase of Tn associated with MUC16 in C1GALT1 KO PDAC 
cells (B) Treatment of control and C1GALT1 KO lysates with PNGase-F and 
neuraminidase identified N-glycosylated and sialylated regions of MUC16 in control and 
KO cells. (Arrows indicate MUC16 band)
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Figure 4.15 
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Figure 4.16 Impact of C1GALT1 KO on MUC4 glycosylation: (A) Left Panel: Western 
blotting demonstrates effective pull-down of MUC4 in control and C1GALT1 KO clones-2 
and 3. Middle panel: Immunoblotting of MUC4-pulled down control and KO lysates with 
STn showed that STn is not present on MUC4 in control and C1GALT1 knockout clones. 
Right panel: Lectin blotting of MUC4-pulled down control and KO lysates with VVA/Tn 
showed that Tn is not present on MUC4 in control and C1GALT1 knockout clones. 
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Figure 4.16 
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Figure 4.17 Upregulation of migratory and tumorigenic genes in C1GALT1 KO PDAC 
cells: Differential gene analysis of RNA-seq data using Cufflinks revealed significant 
upregulation of genes (marked by arrows) in C1GALT1 KO PDAC cells. IPA analysis using 
these upregulated genes indicated their involvement in cancer cell migration and 
tumorigenicity.
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Figure 4.17 
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Figure 4.18 Upregulation of PI3K/Akt signaling in C1GALT1 KO PDAC cells: IPA 
analysis of RNA-seq data from control and C1GALT1 KO PDAC cells indicated 
upregulation of the PI3K/Akt signaling pathway.
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Figure 4.18 
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Figure 4.19 Impact of C1GALT1 KO on EMT markers and signaling proteins: (A) 
Western blotting demonstrates increased expression of phosphorylated forms of signaling 
proteins such as EGFR, HER2 and Akt, whereas their total forms were unchanged. (B) 
Western blotting demonstrates increased expression of the mesenchymal protein 
vimentin, pFAK-Y925, α-4 integrin and decreased expression of epithelial marker ZO-1.
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Figure 4.19 
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Figure 4.20 Impact of pro-inflammatory cytokines on C1GALT1: Treatment of T3M4 
cells with IFN-γ, TNF-α showed slight increase in C1GALT1 expression. On the contrary, 
treatment of T3M4 PDAC cells with high doses of IL-4 and all doses of IL-6 caused a 
decrease in C1GALT1 expression. 
155 
 
 
 
Figure 4.20 
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CHAPTER 5 
Understanding the role of C1GALT1 in pancreatic ductal adenocarcinoma 
progression and metastasis: 
Generation of KrasG12D; Trp53R172H/+; C1galt1loxP/loxP; Pdx1-Cre (KPCC) mice 
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1. Synopsis 
Defective C1GALT1 activity owing to mutations in Cosmc have been reported in 
pancreatic cancer, but its involvement in PDAC progression and metastasis is not well 
defined [1, 2]. We aimed to address this question by generating KrasG12D; Trp53R172H/+; 
C1galt1loxP/loxP; Pdx1-Cre (KPCC) mice that have a pancreas-specific knockout of C1galt1 
along with Kras and p53 mutations. These mice were monitored for tumor progression 
and metastasis at several time points and were compared to KPC mice and their age-
matched littermate controls. Our results indicate that knockout of C1galt1 decreases 
PDAC latency with the appearance of tumors as early as 5 weeks. The majority of 10- and 
15-weeks KPCC mice harbors PDAC, whereas pancreatic intraepithelial neoplasia lesions 
(PanIN) start appearing by 3 weeks. KPCC mice showed a significant decrease in overall 
survival rate as compared to KPC mice. Knockout mice display significantly increased 
expression of truncated Tn glycan structure as compared to KPC mice and control 
littermates. Interestingly, we observed early metastasis in KPCC mice (around 10 weeks) 
as compared to KPC (around 25-30 weeks) mice. There was a remarkable increase of 
vimentin, an EMT marker in C1galt1 knockout mice, which could explain early metastatic 
incidence in these mice. Overall, our findings indicate that genomic depletion of C1galt1 
accelerated PDAC progression and metastasis. 
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2. Background and rationale 
Several spontaneous mouse models of PDAC harboring genomic mutations in 
Kras, p53, and Ink4a and deletions of genes such as Smad4, Shh, and Tgfbr2 have been 
developed in the past few years [3, 4]. All of these mouse models have significantly 
contributed to our understanding of PDAC progression and metastasis. In addition to the 
genetic changes, altered glycosylation also contributes to PDAC growth and metastasis 
[5]. However, the functional contribution of aberrant glycosylation in PDAC progression 
and metastasis is not yet addressed. In an attempt to address this, we generated an O-
glycosylation-deficient PDAC mouse model. In the previous chapter, we have clearly 
illustrated the significant impact of knockout of O-glycosyltransferase, C1GALT1, on tumor 
growth and metastasis. To gain insight into the specific role of C1GALT1 in PDAC 
progression, we have attempted to develop a C1galt1 knockout PDAC mouse model. 
Mouse C1galt1 shares 89% homology with human C1GALT1 and is located on 
chromosome 6 (NCBI BLAST). Therefore, we crossed C1galt1 floxed mice with the KPC 
(KrasG12D; Trp53R172H/+: Pdx-Cre) model of PDAC that resulted in KPCC (KrasG12D; 
Trp53R172H/+; C1galt1loxP/loxP; Pdx1-Cre) mice, which have pancreas specific knockout of 
C1galt1 in addition to Kras and p53 mutations. 
 Disruption of core-1 synthase activity in mice has been associated with embryonic 
lethality, owing to defective angiogenesis that caused hemorrhages in the brain and spinal 
cord [6]. The study by Xia et al. suggested that angiogenic defects in C1galt-/- mice might 
be caused by abnormal glycosylation of cellular components constituting vascular network 
such as endothelial cells and pericytes [6]. Another study from the same group 
demonstrated that mouse with targeted deletion of C1galt1 in endothelial and 
hematopoietic cells had improper connections among blood and lymphatic vessels [7]. 
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Disturbance in blood/lymphatics network impaired transport of lipids resulting in fatty liver 
disease [7]. Further studies using targeted deletion of C1galt1 in spermatogonia and 
oocytes have established the roles of core-1 glycans in proper embryonic development 
and spermatogenesis respectively [8, 9]. Interestingly, intestinal knockout of C1galt1 was 
associated with the spontaneous development of colitis and colitis-associated cancer due 
to disruption of mucus barrier suggesting the protective role of core-1 glycans in the 
intestine [10, 11]. Altogether, these studies suggest that loss of C1galt1 is associated with 
increased expression of truncated Tn carbohydrate glycans and hence the resultant 
pathology.  
Apart from the aforementioned pathological conditions, numerous studies have also 
reported increased expression of truncated carbohydrate antigens such as Tn, STn in 
several malignancies including PDAC [12, 13]. Loss of expression of C1GALT1 is one of 
the mechanisms that results in increased expression of truncated carbohydrate antigens. 
Loss of C1GALT1 has been linked to mutations in Cosmc, which facilitates its proper 
folding and thereby prevents its proteasomal degradation [14].  Radhakrishnan et al. have 
demonstrated that epigenetic changes in Cosmc due to promoter hypermethylation is 
associated with loss of expression of C1GALT1 and increased activation of Tn 
carbohydrate antigen [2]. Further, the same study, and another study from Hoffman et al 
have demonstrated that knockout of Cosmc in PDAC cells leads to increased expression 
of truncated carbohydrate antigens and enhanced oncogenicity [1]. Though these studies 
have revealed an important role of Cosmc in PDAC, the possibility that Cosmc knockdown 
has other biological effects cannot be excluded. The precise role of C1GALT1 in PDAC 
progression and metastasis is still unclear. 
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 The objective of our study was to examine the functional impact of core-1 
knockout-mediated aberrant O-glycosylation on PDAC progression and metastasis. For 
this purpose, the study herein involved generation of C1galt1 knockout PDAC model.  
Detailed characterization of KPCC mice revealed that loss of C1galt1 in KPC mice (KPCC 
mice) induced truncated glycophenotype and facilitated faster PDAC progression and 
early metastasis. 
 
3. Results 
A. Development of KPCC mouse model 
Previous studies have described that genomic instability conferred by endogenous 
expression of Trp53R172H and KrasG12D in the mouse pancreas leads to spontaneous 
development of pancreatic ductal adenocarcinoma [15]. To explore the role of C1galt1 in 
pancreatic cancer, these KPC mice (KrasG12D; Trp53R172H/+; Pdx-Cre) were bred with 
C1galt1 floxed (C1galt1loxP/loxP) mice that resulted in KPCC mice (KrasG12D; Trp53R172H/+; 
C1galt1loxP/loxP; Pdx-Cre). C1galt1 floxed mice (C1galt1loxP/loxP) were a kind gift from Dr. 
Lijun Xia and have been described in his previous studies [10, 11, 16]. The breeding 
strategy for the generation of KPCC mice has been outlined in Figure 5.1.  
 
B. Deletion of C1galt1 leads to faster PDAC progression and decreased survival 
We noted that knockout of core-1 synthase in the context of KPC background 
accelerated development of PDAC (Figure 5.2A).  Low-grade PanIN1 and 2 lesions were 
observed as early as 3 weeks (Figure 5.2B). At 5 weeks, 25% of KPCC mice display high-
grade PanIN3 lesions, which increased to 60% by 10 weeks. The development of these 
high-grade lesions was very rapid as compared to KPC mice, which usually develop these 
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high-grade lesions by 10 weeks. Since these high-grade benign lesions (also known as 
Carcinoma in situ) eventually leads to PDAC development, KPCC was evaluated at 
different time points, starting from 3 weeks to 20 weeks, to monitor PDAC progression 
(Figure 5.1, Figure 5.2B). Fully blown pancreatic tumors were apparent as early as 5 
weeks (40%)  and majority of 15 weeks (60%) and 20 weeks KPCC (80%) animals 
exhibited PDAC (Figure 5.3A). Histopathologic analysis of KPCC tumors revealed poorly 
differentiated/undifferentiated morphology (sarcomatoid histology, many gigantic cells, 
and atypical mitotic figures) however, a vast majority of KPC animals showed well to 
moderately differentiated tumors (Figure 5.3B). Notably, the pancreas appeared normal 
when C1galt1 was deleted (C1galt1loxP/loxP; Pdx-Cre) without the background of Kras and 
p53 gene mutations. This suggests that targeted deletion of C1galt1 in mouse pancreas 
did not affect its development (Figure 5.4). Nevertheless, loss of C1galt1 in conjunction 
with mutated Kras and p53 significantly accelerated disease progression. 
Since knockout of C1galt1 in PDAC induced faster disease progression, we also 
evaluated its effect on overall survival. Previous studies have reported that the median 
survival rate of KPC animals is around 200 days. Survival studies were conducted to 
explore the effect of C1galt1 deficiency in the background of KPC. The mean survival of 
KPC control littermates was around 205 days (29.2 weeks), whereas KPCC mice have 
dramatically shortened median survival of 107 days (15.2 weeks) (Figure 5.5). Taken 
together, these findings suggest that knockout of C1galt1 along with Kras and p53 
mutations significantly augments PDAC initiation and impacts survival.  
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C. Fully blown pancreatic tumors in KPCC mice displayed numerous mitotic figures 
and decreased stroma  
To evaluate the effect of C1galt1 knockout on cell proliferation, we counted mitotic 
figures in KPC and KPCC tumors. KPCC tumors showed numerous mitotic figures as 
identified by H and E staining. We also observed increased presence of atypical mitotic 
figures (gigantic nucleus with scarce cytoplasm) in KPCC tumors. Increased presence of 
these mitotic figures and atypical nuclear structures marks aggressive malignancy and 
has been used for clinical grading of several tumors (Figure 5.6) [17].  
We next sought to determine whether loss of C1galt1 has any effect on fibrosis, 
which is highly observed in PDAC and is frequently observed in tissue histology [18]. We 
first stained KPC and KPCC tumors with alpha-SMA, which has been widely used to 
identify cancer-associated fibroblasts in the stroma. C1galt1 lacking tumors showed 
significantly decreased alpha-SMA expression in comparison to KPC tumors, which 
showed appreciable levels of alpha-SMA (Figure 5.7). Next, to verify changes in the 
stroma, we analyzed collagen content using Picro-Sirius red staining. Consistent with 
alpha-SMA staining, the percentage of Sirius red-stained area was also significantly 
reduced in KPCC tumors as compared to KPC tumors (Figure 5.8). Our findings are 
consistent with recent studies that have described findings showing that targeting stroma 
renders PDAC more aggressive [19]. Taken together, these results indicate that loss of 
C1galt1 leads to the formation of aggressive PDAC tumors with a marked decrease in 
stroma.   
 
D. Truncated glycophenotype of KPCC mice 
Next, we investigated whether increased PDAC aggressiveness in KPCC tumors 
is due to differential glycosylation by the loss of C1galt1. The effect of C1galt1 knockout 
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on glycosylation was assessed using Alcian blue and lectin staining. Alcian blue staining 
revealed a marked decrease of sulfated/sialylated (acidic) glycans in KPCC tissues in 
comparison with KPC tissues (Figure 5.9). Since C1galt1 catalyzes the formation of core-
1/T carbohydrate antigen, we evaluated its expression in KPC and KPCC tumors 
(pretreated with neuraminidase) using PNA-Rhodamine [20]. As expected loss of C1galt1 
in KPCC tumors led to a significant decrease in T carbohydrate antigen as compared to 
KPC tumors. This further confirmed effective knockout of C1galt1 in KPCC mice (Figure 
5.10).  
We next stained the KPC and KPCC tumors with VVA lectin, which is used to 
visualize Tn carbohydrate antigen (Figure 5.11). Increased expression of truncated Tn 
carbohydrate antigen is frequently observed in several malignancies and correlates with 
their increased aggressiveness [21]. KPCC mice showed a significant increase in Tn 
carbohydrate antigen as compared to KPC mice (Figure 5.11). Taken together, these 
findings indicate that knockout of C1galt1 in PDAC results in aberrant expression of Tn 
carbohydrate antigen and loss of core-1 O-glycan structures. 
 
E. Increased metastasis incidence upon loss of C1galt1 in KPC mice 
We observed early metastatic lesions in KPCC mice (5 weeks) as compared to KPC 
mice, which shows late metastasis (Figure 5.12A) [15]. We did not observe any 
metastasis in KPC mice until 20 weeks. Figure 5.12A outlines representative pictures 
showing metastasis to several organs such as liver, peritoneum, and stomach in KPCC 
mice. Further, we also evaluated RNA collected from KPC and KPCC tumors for EMT 
markers.  We noticed increased expression of the mesenchymal protein vimentin whereas 
epithelial makers such as keratins (keratin-5 and -7) and claudins (claudin-4 and -6) were 
decreased (Figure 5.12B). To better understand the mechanism involved in early 
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metastasis, the sections were stained with metastatic marker vimentin. KPCC tumors 
showed a remarkable increase in vimentin as compared to KPC tumors (Figure 5.13). 
These results suggest increased metastatic incidence in KPCC mice as compared to KPC 
mice, which could be explained by increased expression of vimentin in KPCC tumors as 
compared to KPC tumors. 
 
F. Development of cell lines and organoids from KPC and KPCC tumors 
Since mouse model-derived cell lines represent valuable tools to understand 
PDAC biology and for drug treatment studies, we have developed four cell lines from 
tumors derived from KPC mouse model (Y846, KCT-3129, KCT-3248, KCT-3266) (Figure 
5.14A) [22, 23] . Additionally, we have also developed three cell lines from primary tumors 
(Y543, Y609, Y841) and one cell line from a liver metastasis of KPCC (Y841-LM) mouse 
model. Representative morphology of some of these cell lines is outlined in Figure 5.14B. 
Preliminary characterization of some of these KPCC cell lines showed increased 
expression of Tn and STn carbohydrate antigens as compared to the well-characterized 
Fc-1295 KPC cell line. Expression of CK-19 in all the cell lines suggests their ductal origin. 
Further, comparison of KPC and KPCC cell lines will unveil the mechanisms underlying 
increased aggressiveness of C1galt1 knockout tumors. 
Along with the cell lines, we have also developed organoids from KPC tumors 
(Y846, Y3129) [24]. Figure 5.15 outlines representative pictures of KPC organoids. We 
are in the process of generating KPCC organoids. Comparative studies with KPC and 
KPCC organoids will further help us in understanding the role of C1galt1 in PDAC. 
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4. Discussion 
Evidence of increased presence of unusual/aberrant carbohydrate antigens dates 
back to 1990s. Pioneer studies focused on pancreatic cancer glycobiology have shown 
the expression of several incomplete/truncated carbohydrate antigens such as Tn, T and 
STn in intraductal papillary-mucinous neoplasm, chronic pancreatitis and pancreatic 
cancer tissues [25, 26]. These studies report differential expression of these carbohydrate 
antigens in all of these pathological states of the pancreas. For instance, Itzkowitz et al. 
have demonstrated marked increase of STn in pancreatic cancer (expressed by 97% of 
cancer tissues), while it is not expressed by normal pancreas [25]. On the contrary, 
expression of T carbohydrate structure was observed in normal acinar structures, but only 
48% of pancreatic cancer tissues express this carbohydrate antigen [25]. Relatively 
increased presence of one carbohydrate antigen over the other suggests that expression 
of glycosyltransferases that synthesize these carbohydrate antigens is modulated with 
PDAC progression. The notion of aberrant glycosylation in PDAC was further bolstered by 
a recent study from Dr. Remmers et al. that has also demonstrated differential expression 
of glycans in PDAC [13]. In particular, the study established differential glycosylation of 
MUC1 and MUC4 during PDAC progression [13].  
 Though these studies provide insights in to aberrant glycosylation in PDAC, it is 
really important to understand the underlying mechanism of aberrant glycosylation and 
how aberrant glycosylation induces PDAC progression. As discussed previously, altered 
expression of glycosyltransferases could potentially induce expression of aberrant 
carbohydrate antigens. In this context, study by Radhakrishnan and Hoffman et al. have 
demonstrated that loss of Cosmc, a chaperone for glycosyltransferase C1GALT1 leads to 
aberrant O-glycosylation and increased aggressiveness [1, 2]. Though these studies have 
indicated an essential role of C1GALT1 chaperone (Cosmc) in PDAC, precise roles of 
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C1GALT1 in PDAC need to defined. Another critical aspect that needs to be explored is 
how aberrant glycosylation impacts PDAC progression and metastasis. 
Our study is a maiden attempt to study the aberrant role of glycosylation in PDAC 
progression using genetically engineered mouse models. Although several animal models 
of PDAC have been established in the past few years, a genetically engineered mouse 
model that addresses the specific contribution of truncated O-glycans in PDAC 
progression is not yet described. In an effort to explore the role of truncated O-glycans in 
PDAC, we attempted to develop an animal model of PDAC that has truncated O-glycans. 
As discussed previously in Chapter 4 that loss of C1galt1 in PDAC cancer cells leads to 
truncated glycans, we developed the KPCC model that has pancreas-specific C1galt1 
depletion along with Kras and p53 mutations. We observed that loss of C1galt1 in the 
context of already established tumor setting (Kras and p53 mutations) significantly 
affected PDAC latency. PanIN (pancreatic intraepithelial neoplasia) lesions were noticed 
in 3-weeks-old KPCC mice. This finding was quite intriguing, as this early lesion 
development has not been observed with KPC mice. PanIN initiation was observed at 
around 5-weeks in KPC mouse model. Strikingly, loss of C1galt1 along with Kras and p53 
mutations in mouse pancreas significantly reduced survival of mice in comparison with 
mice that have only Kras and p53 mutations. The median survival of KPCC mice was 
around 15 weeks as compared to 28 weeks for KPC mice. 
Tissue histology revealed poorly differentiated/undifferentiated morphology of 
these tumors as compared to KPC tumors that are more differentiated. KPCC tumors were 
highly proliferative as assessed by mitotic figure count. We assessed desmoplasia in 
KPCC and KPC tumors using alpha-SMA and Sirius red staining. Increased desmoplasia 
is one of the characteristic features of pancreatic tumors and adversely affects PDAC 
outcome [27]. We noticed that there is diminished fibrosis in KPCC tumors as compared 
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to KPC tumors. This contradictory finding is in agreement with a previous study by Rhim 
et al. that demonstrates increased aggressiveness of PDAC with less stroma [19]. The 
study targeting Shh signaling (important in fibrosis) points to the extensive proliferation of 
tumor cells in the absence of stroma [19]. We observed a similar tumor phenotype with 
C1galt1 knockout in KPCC mice. Two possibilities may account for this aggressive 
phenotype. First, loss of C1galt1 leads to significant increase in proliferation of tumor cells 
that overnumbers the stromal component. Another is loss of C1galt1 decreases growth of 
stromal population and hence gives a chance to tumor cells to expand. Our results from 
CRISPR/Cas9-based knockout of C1GALT1 in human PDAC cells (Chapter-4 of 
dissertation) support the first possibility as we observed increased tumorigenicity of 
C1GALT1 KO PDAC cells. However, specific experiments need to be performed to test 
this paradoxical finding.  
Interestingly, we observed early metastasis in KPCC tumors (5 weeks) as compared to 
KPC tumors, which develops late metastasis (20-25 weeks). KPCC is the first PDAC 
model to show very early metastasis (5 weeks), compared to other PDAC animal models 
developed so far. To understand the molecular mechanism involved in increased 
metastasis, we analyzed EMT markers in KPC and KPCC models, due to the spindled 
morphology of tumor cells in the KPCC model. It is well known that EMT is the initial step 
for the metastatic cascade [28]. The assessment of EMT markers in KPC and KPCC 
tumors revealed increased expression of a mesenchymal marker, vimentin and decreased 
expression of several epithelial markers such as claudins and keratins [29]. Further, we 
stained KPC and KPCC tumors for the mesenchymal protein vimentin [30]. Increased 
vimentin expression allows cells to gain mesenchymal phenotype and hence increased 
migration and metastasis [31]. There was a remarkable increase in vimentin expression 
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in KPCC tumors as compared to KPC tumors. Overall, this result suggests that increased 
expression of vimentin with depletion of C1galt1 may lead to early metastasis of PDAC.  
To investigate if the observed aggressive phenotype is linked to altered 
glycosylation, we stained KPC and KPCC tumors with alcian-blue, PNA-Rhodamine and 
VVA-Fluorescein. Assessment of O-glycans via these carbohydrate specific stains 
demonstrated significantly altered glycosylation in KPCC pancreatic tumors as compared 
to KPC. In particular, we have observed increased expression of truncated Tn 
carbohydrate antigen. Truncated glycosylation on proteins has been shown to activate 
signaling molecules, possibly via relief of steric hindrance imparted by extended glycan 
structures. Further, the increased expression of truncated glycans has been shown to 
facilitate disease progression and metastasis by interacting with lectins such as galectins 
and Siglecs [32]. However, the possible involvement of such carbohydrate interactions in 
aggressiveness of KPCC tumors needs to be explored. Collectively, our study highlights 
the significant involvement of loss of C1galt1 expression in PDAC progression and 
metastasis. Since increased expression of Tn carbohydrate antigen in KPCC mouse 
models aggravates PDAC progression, our study holds potential clinical implications. 
Assessment of C1GALT1/Tn carbohydrate antigen in PDAC patients can predict disease 
severity. So far, CA-19.9 is one of the prognostic tests for PDAC [33, 34]. However, 
sensitivity and specificity of this serological assay needs to be improved. Further, a subset 
of patients does not express CA19.9 [35]. We speculate that assessing C1GALT1/Tn 
carbohydrate antigen in PDAC patients, especially for this subset of patients, can be of 
great benefit. Additionally, since the KPCC model represents faster PDAC progression 
model, we believe that this model could be used in pre-clinical studies to test the effect of 
several therapeutic agents on PDAC growth and metastasis. Together, the findings from 
our study indicate that knockout of C1galt1 in already established tumor setting (Kras and 
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p53 mutations) caused aberrant glycosylation that decreased PDAC latency and 
increased tumor progression and metastasis .
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Figure legends 
Figure 5.1: Schematic representation of the breeding strategy for the development 
of KrasG12D; Trp53R172H/+; C1galt1loxP/loxP; Pdx1-Cre (KPCC) mouse model to 
investigate the role of C1galt1 in PDAC progression and metastasis: KrasG12D; Pdx1-
Cre and LSLTrp53R172H/+ were crossed with C1galt1loxP/ loxP mice separately to obtain the 
F1 progeny with KrasG12D; Pdx1-Cre; C1galt1+/loxP and LSLTrp53R172H/+; C1galt1+/loxP 
genotype. Intercrossing of F1 progeny resulted in KrasG12D; Trp53R172H/+; C1galt1loxP/loxP; 
Pdx1-Cre (KPCC) mouse model. Following birth, the F2 progeny was then euthanized at 
3, 5, 10, 15 and 20 weeks of age to analyze pancreatic cancer progression in the absence 
of C1galt1.
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Figure 5.2: Loss of C1galt1 resulted in faster PDAC progression: (A) Gross 
appearance of pancreatic tumors in KPC and KPCC mice. Large pancreatic tumor was 
seen for KPCC mice at around 10 weeks as compared to 28 weeks KPC mice with a small 
tumor. (B) Representative histological pictures of the pancreas from age-matched control, 
KPC and KPCC mice at 3, 5, 10, 15 and 20 weeks. (n=5 for control, KPC and KPCC mice). 
H and E stained pictures reveal the appearance of neoplastic lesions at around 3 weeks 
in KPCC mice as compared to KPC mice, which has a normal pancreas. Tumors were 
seen in 10-, 15 and 20-weeks old KPCC mice. However, KPC mice showed late tumor 
development at around 20 weeks. All the pictures were taken at 20X magnification.
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Figure 5.3: Early tumor development in KPCC mice: (A) Increased percentage of 
tumor-bearing animals was observed in KPCC cohort as compared to KPC cohort at 5, 
10, 15 and 20 weeks. (B) Representative H and E stained picture of pancreatic tumors 
from 30-week old KPC and 10-week old KPCC mice. KPC mice pancreatic tumors 
displayed well-differentiated pancreatic tumor histology, whereas poorly 
differentiated/undifferentiated tumor histology was observed for KPCC tumors. Whole 
slides containing pancreatic sections were scanned at TSF and the enlarged pictures 
represent 40X magnification. 
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Figure 5.4 C1galt1 depletion in mouse pancreas did not affect pancreatic 
development: H and E stained pictures from two 4-weeks old C1galt1 loxP /loxP ; Pdx1-Cre 
mice demonstrates that C1galt1 deletion in mouse pancreas have no effect on its 
development. Pancreas from C1galt1 loxP /loxP ; Pdx1-Cre mice showed normal islets and 
acinar structures. 
180 
 
 
 
Figure 5.4 
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Figure 5.5: Knockout of C1galt1 significantly decreased overall Survival: Survival 
analysis of KPC and KPCC mice using Kaplan-Meier approach shows that genomic 
depletion of C1galt1 in KPCC mice significantly decreased median survival as compared 
to KPC mice. (n=11 for KPC and n=8 for KPCC). KPCC mice has significantly decreased 
median survival (107 days) as compared to KPC mice (205 days)
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Figure 5.6: Increased proliferation of KPCC tumors as compared to KPC tumors: 
Top panel:  Proliferation of KPC and KPCC tumors was assessed by counting mitotic 
figures (cells undergoing mitosis). Bar diagram demonstrates significant increase of 
mitotic figures in KPCC tumors as compared to KPC tumors (n=3 for KPC and KPCC 
mice); Bottom panel: Representative histologic pictures showing increased presence of 
typical and atypical mitotic figures in KPCC mice as compared to KPC mice. Enlarged 
pictures represent abnormal/dividing nuclear structures. Representative pictures were 
taken at 20X magnification. Error bars represent mean ± s.e.m. *P<0.05; by unpaired two-
sided Student’s t-test.
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Figure 5.7: Decreased alpha-SMA in KPCC tumors: Top panel: Cancer-associated 
fibroblasts in KPC and KPCC pancreatic tumors were examined using alpha-SMA 
staining. Scatter dot plot demonstrates significant decrease of alpha-SMA composite 
score in KPCC tumors as compared to KPC tumors (n=6 for KPC and KPCC mice); 
Bottom panel: Representative histologic pictures showing decreased alpha-SMA staining 
in KPCC tumors as compared to KPC tumors. Error bars represent mean ± s.e.m. 
*P<0.05; by Wilcoxon Signed Rank Test. (B) Top panel: Significant decrease in mean 
fluorescent intensity of alpha-SMA in KPCC pancreatic tumors as compared to KPC 
tumors. Bottom panel: Representative immunofluorescent pictures showing decreased 
alpha-SMA staining in KPCC pancreatic tumors as compared to KPC pancreatic tumors 
(n=5 for KPC and KPCC mice). Error bars represent mean ± s.e.m. **P<0.005; by Mann 
Whitney test.
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Figure 5.8: Decreased fibrosis in KPCC tumors: Top panel: Fibrosis in KPC and KPCC 
pancreatic tumors was asessed using Picro-Sirius red staining. Sirius red-stained area in 
KPC and KPCC tumor nodules was quantified using Definiens software (Tissue Science 
Facility, UNMC). Bar diagram demonstrates significant decrease of percentage of Sirius 
red-positive area in KPCC tumors as compared to KPC tumors. (n=5 for KPC and KPCC 
mice); Bottom panel: Representative histologic pictures showing decreased percentage 
of Sirius red-stained area in KPCC mice as compared to KPC mice. Whole slides 
containing pancreatic sections were scanned at TSF and the enlarged pictures represent 
40X magnification. Error bars represent mean ± s.e.m. *P<0.05; by unpaired two-sided 
Student’s t-test.
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Figure 5.9: Decreased Alcian blue staining in KPCC tumors: KPC and KPCC tissue 
sections collected at different time points were stained with Alcian blue to assess the 
impact of C1galt1 knockout on O-glycans. Alcian blue is commonly used to visualize acidic 
(sulfated/sialylated) glycans. Top panel:  Box and whiskers plot showing significant 
decrease of Alcian blue composite score in KPCC tumors, as compared to KPC tumors, 
at different time points; Bottom panel: Representative histologic pictures showing strong 
Alcian blue positivity in mucinous neoplastic pancreatic ducts of KPC mice, whereas trace 
to weak positivity was seen for KPCC pancreatic ducts. (n=4-5 for KPC and KPCC mice; 
*p<0.05; **p<0.05). Representative pictures were taken at 20X magnification. *P<0.05; by 
Mann Whitney test.
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Figure 5.10: Loss of T carbohydrate antigen with knockout of C1galt1 in KPCC mice: 
KPC and KPCC tumor sections were stained with PNA-Rhodamine to evaluate the impact 
of C1galt1 knockout on the T carbohydrate antigen synthesis (catalyzed by C1galt1). (A) 
Treatment of PDAC tissue with neuraminidase that cleaves sialic-acids resulted in 
exposure of T-carbohydrate antigen and hence increased binding of PNA-Rhodamine to 
T carbohydrate antigen in the neoplastic ducts. (n=4 for KPC and KPCC mice (B) Top 
panel: Bar diagram depicts significant decrease of mean fluorescent intensity of T 
carbohydrate antigen in KPCC tumors as compared to KPC tumors; Bottom panel: 
Representative fluorescent pictures and histograms showing decreased T carbohydrate 
antigen staining in neoplastic pancreatic ducts of KPCC mice as compared to KPC mice. 
Error bars represent mean ± s.e.m. *P<0.05; by Mann Whitney test.
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Figure 5.11: Aberrant expression of truncated Tn carbohydrate antigen in KPCC 
mice: KPC and KPCC tumors were probed with VVA-Fluorescein to evaluate the impact 
of C1galt1 knockout on Tn carbohydrate antigen (catalytic substrate for C1galt1). Top 
panel: Bar diagram depicts significant increase of mean fluorescent intensity of Tn 
carbohydrate antigen in KPCC tumors as compared to KPC tumors (n=6 for KPC and 
KPCC). Bottom panel: Representative fluorescent pictures and histograms showing 
increased Tn carbohydrate antigen staining in KPCC mice as compared to KPC mice. 
Error bars represent mean ± s.e.m. **P<0.005; by Mann Whitney test.
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Figure 5.12 Loss of C1galt1 resulted in enhanced metastasis: (A) Left panel: Bar 
diagram demonstrates increased percentage of animals with metastasis in KPCC mice as 
compared to KPC mice at different time points (n=5 for KPC and KPCC mice) Right panel: 
Representative H & E pictures showing metastatic lesions in peritoneum, oviduct, liver 
and stomach in KPCC mice. (B) RT-PCR analysis of several EMT genes shows significant 
increase of mesenchymal marker vimentin and significant decrease of epithelial markers, 
keratin-5, keratin-7, claudin-4 and claudin-6. Error bars represent mean ± s.e.m. * P<0.05, 
**P<0.005; by unpaired two-sided Student’s t-test.
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Figure 5.13 Remarkable increase of vimentin expression in KPCC pancreatic 
tumors: (A) Top panel: Significant increase in mean fluorescent intensity of vimentin in 
KPCC pancreatic tumors as compared to KPC tumors. Bottom panel: Representative 
immunofluorescent pictures showing increased vimentin staining in KPCC pancreatic 
tumors as compared to KPC pancreatic tumors (n=6 for KPC and KPCC mice). (B) Top 
panel: Asessment of vimentin staining in pancreatic tumor cells of KPC and KPCC mice 
reveals significant increase of vimentin composite score in KPCC pancreatic tumors as 
compared to KPC (n=7 for KPC and KPCC mice). Bottom panel: Representative 
immunohistochemical pictures showing increased vimentin staining in KPCC pancreatic 
tumors as compared to KPC pancreatic tumors. Error bars represent mean ± s.e.m. 
**P<0.005; by Mann Whitney test.
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Figure 5.14: Characterization of murine cell lines derived from KPC and KPCC 
tumors: The role of C1galt1 in PDAC was studied by development of cancer cell lines 
from KPC and KPCC tumors. (A) Representative morphology of KPC (top panel) and 
KPCC (bottom panel) pancreatic tumor cell lines. (B) Left panel depicts DNA gel picture 
showing knockout of C1galt1 in KPCC cell lines as compared to KPC cell line. Right panel 
demonstrates increased expression of Tn and STn truncated carbohydrate antigens in 
KPCC cell lines as compared to the KPC cell line. All the cell lines express CK-19, however 
the expression of CK-19 was decreased in one of the KPCC cell line (Y609) as compared 
to Y543 and Fc-1295.
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Figure 5.15: Development of KPC tumor organoids: 3-D organoid system was 
developed from KPC mice that recapitulates in vivo PDAC histology. (A) 
Representative microscopic pictures of organoids developed from KPC tumors shows 
ductal structures. Fibroblast like structures (marked by arrow) were also noticed among 
organoids, indicating the presence of tumor microenvironment components in 3-D 
organoid cultures. (B) Representative H and E stained pictures of organoids sections 
showing ductal structures.
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CHAPTER 6 
Summary, Conclusions and Future directions
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1. Summary 
Aberrant O-glycosylation is one of the hallmarks of pancreatic cancer [1, 2]. Mucin-
type O-glycosylation involves a plethora of glycosyltransferases [3]. Alterations in the 
expression/activity of O-glycosyltransferases results in aberrant O-glycosylation, which 
has been shown to play an important role in cancer progression and metastasis [2].  
 Aberrant O-glycan structures include truncated carbohydrate structures such as 
Tn, STn, T, ST. These have been named as tumor-associated carbohydrate antigens 
(TACA) because these are not observed under normal conditions, as they are masked by 
addition of several carbohydrate moieties [4]. However, under malignant conditions, these 
cryptic glycan structures are exposed because of altered activity of glycosyltransferases. 
Differential expression of these truncated carbohydrate antigens has been reported in 
several malignancies including PDAC [5, 6]. However, several aspects of aberrant 
glycosylation remain unanswered. For instance, what are the specific roles played by 
these truncated glycans in PDAC progression and metastasis? In this context, how does 
differential expression of glycosyltransferases contribute to PDAC progression and 
metastasis? We have attempted to address parts of these questions through the studies 
presented in this thesis. 
 The major focus of the studies presented in this thesis is to examine the role of 
aberrant glycosylation in PDAC progression. Briefly, we have examined the role of two 
glycosyltransferases in this aspect. To achieve this, we have designed three major goals. 
First, we investigated the role of one of the members of the O-glycosylation-initiating 
enzyme family, GALNT3, in PDAC aggressiveness. Secondly, we explored the functional 
implications of the loss of C1GALT1 (the second enzyme of the mucin-type O-
glycosylation pathway) in PDAC. Finally, to understand the role of C1GALT1 in PDAC 
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progression and metastasis, we generated a mouse model of PDAC that has loss of 
C1galt1. 
Concisely, we have observed that loss of both of the O-glycosyltransferases leads to 
altered glycosylation and increased aggressiveness. Further, loss of C1galt1 in a PDAC 
mouse model resulted in reduced overall survival, faster PDAC progression and increased 
metastasis. Loss of GALNT3 induced aberrant glycosylation on EGFR and Her2, whereas 
loss of C1GALT1 induced aberrant MUC16 glycosylation. Aberrant glycosylation of these 
proteins could be the plausible mechanism by which PDAC cells acquire increased 
aggressiveness. The summary of all the three projects is described below: 
 
A. Loss of GALNT3 in poorly differentiated cancer leads to increased 
aggressiveness 
 The rationale of this study is based on previous studies in lung, gastric and colon 
adenocarcinoma, where patients with decreased expression of GALNT3 showed poor 
survival [7-10]. Further, prior studies have also shown decreased expression of GALNT3 
expression in poorly differentiated PDAC [11, 12]. However, limited information is available 
on the role of GALNT3 in PDAC. First, we examined the expression of GALNT3 in a panel 
of pancreatic cancer cell lines and tissues derived from different grades of cancer (ranging 
from well differentiated to poorly differentiated). We did not observe GALNT3 expression 
in poorly differentiated PDAC cells. However, well/moderately differentiated PDAC cells 
were found to express GALNT3. Similarly, poorly differentiated PDAC tissues showed 
weak and less staining of GALNT3 as compared to well/moderately differentiated PDAC. 
 Having established that there is no/reduced GALNT3 expression in a poorly 
differentiated subtype of PDAC, we wanted to understand the impact of its loss on disease 
aggressiveness. Therefore, we performed stable knockdown of GALNT3 in four different 
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PDAC cell lines. Knockdown of GALNT3 resulted in slightly decreased expression of Tn 
carbohydrate antigen. Further, there was altered expression of poorly differentiated PDAC 
markers. Increased expression of Sox-2 and decreased expression of CA19.9 was seen 
in GALNT3-knockdown PDAC cells as compared to control cells. 
 We next examined the impact of GALNT3 loss on PDAC by performing in vitro 
growth and migration assays in control and GALNT3 knockdown PDAC cells. In vitro 
functional studies revealed increased growth and migration of GALNT3-knockdown in 
PDAC cells. Some of the proteins involved in increased growth and motility were also 
evaluated in control and GALNT3-knockdown cells. GALNT3 knockdown showed 
increased expression of cyclin A, ZEB-1, N-cadherin and vimentin and decreased 
expression of E-cadherin. We observed increased expression of carbohydrate antigen 
SLex in GALNT3 knockdown PDAC cells. Since SLex have been implicated in 
extravasation by mediating attachment of tumor cells with the endothelial cells, we 
conducted tumor-endothelium adhesion assay [13]. GALNT3-knockdown cells showed 
significantly increased adhesion to endothelial cells monolayer as compared to control 
cells. 
 Mechanistic insights were provided by protein expression studies, where we 
observed increased phosphorylation of ErbB receptors such as EGFR, Her2, and Her3. 
To specifically understand how the loss of a glycosyltransferase is causing increased 
activation of ErbB receptors, we examined glycosylation alterations on these receptors. 
Recent studies have established the link between glycosylation and activation of EGFR 
[14, 15]. Therefore, we carried out lectin-pull down assay using VVA and PNA lectin that 
pulls down Tn and T carbohydrate antigen, respectively. Lectin-pull down study 
demonstrated increased expression of Tn and T carbohydrate antigen on EGFR and Her2. 
This increase in truncated carbohydrate antigens on EGFR and Her2 could be explained 
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by the compensatory increase of other GALNTs such as GALNT2. Our conclusion from 
the first part of the study is that expression of GALNT3 is reduced in poorly differentiated 
PDAC and loss of this glycosyltransferase is associated with increased aggressiveness 
and altered glycosylation on ErbB receptors. 
 
B. C1GALT1 knockout in PDAC cells leads to increased tumor growth and 
metastasis 
 Given the fact that loss of C1GALT1 leads to the formation of truncated glycans in 
cancer, and the recent studies that indicate loss of C1GALT1 activity in PDAC patients; 
we decided to investigate whether loss of C1GALT1 in PDAC is associated with aberrant 
glycosylation and increased aggressiveness [5, 16].  
 As a part of this project, RNA and tissues collected from a panel of pancreatic 
cancer patients were profiled for C1GALT1 expression. C1GALT1 was not expressed in 
the majority of PDAC cases examined. We further observed decreased C1GALT1 
expression in fully transformed HPNE cells as compared to untransformed HPNE cells. 
All of these studies suggests that loss of C1GALT1 might mediate increased 
aggressiveness.   
The specific role of C1GALT1 in PDAC was studied by CRISPR/Cas9-mediated 
knockout of C1GALT1 in three different PDAC cancer cells. As expected, all the C1GALT1 
knockout cells showed truncated glycophenotype. Functional studies showed increased 
migration of C1GALT1-knockout PDAC cells. We also developed a migratory model of 
PDAC to evaluate if highly migratory cells modulate C1GALT1 expression. Highly 
migratory sublines showed decreased expression of C1GALT1 as compared to parental 
cells. Our in vitro results instigated examination of the impact of C1GALT1 knockout on 
tumorigenicity and metastasis. Orthotopic implantation of two different C1GALT1 knockout 
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clones yielded significantly increased tumor weights and metastatic lesions as compared 
to control cells.  
Our next focus was to understand the molecular mechanism by which loss of an 
O-glycosyltransferase leads to increased tumorigenicity and metastasis. We evaluated the 
expression of mucins, which are amongst the heavily glycosylated proteins and play 
pivotal role in PDAC growth and metastasis. C1GALT1-knockout cells showed decreased 
expression of mucins such as MUC1 and MUC4. Interestingly, we observed molecular 
weight shift of MUC16 but not MUC4 and MUC1. Lectin pull down assay and glycan 
cleaving enzymatic assays demonstrated that altered glycosylation accounts for observed 
shifts in molecular weight. Tn was remarkably increased on MUC16 in C1GALT1 knockout 
cells as compared to control cells. Further, RNA-seq data provided detailed insights in to 
the molecular mechanism by which altered glycosylation is causing increased 
aggressiveness. We observed differential expression of several tumorigenic and migratory 
genes in C1GALT1 KO PDAC cells. In line with these findings, we also observed increased 
activation (phosphorylation) of oncogenic signaling proteins such as EGFR and Her2, and 
mesenchymal markers, vimentin and pFAK-Y925, whereas expression of the epithelial 
marker, ZO-1 was decreased in C1GALT1 knockout-PDAC cells. 
Our conclusion from this part of the study is that knockout of C1galt1 in PDAC 
leads to increased tumorigenicity and metastasis possibly via aberrant MUC16 
glycosylation. 
 
 C. Genomic depletion of C1galt1 accelerates PDAC progression and metastasis 
 Our in vitro studies with human PDAC cells indicated the significant impact of the 
loss of O-glycosyltransferase C1GALT1 on tumor growth and metastasis. In this part of 
the project, we sought to study the role of C1GALT1 in PDAC progression and metastasis. 
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Conventional KPC (KrasG12D; Trp53R172H/+; Pdx1-Cre) model of PDAC progression was 
crossed with C1galt1loxP/loxP mice, resulting in the KPCC (KrasG12D; Trp53R172H/+; 
C1galt1loxP/loxP; Pdx1-Cre) model. KPC mice and age-matched control littermates were 
used as controls in our study. PDAC progression in KPCC mice was compared to KPC 
mice. Knockout of C1galt1 specifically in the pancreas with the background of Kras and 
p53 mutations lead to decrease tumor latency. KPCC mice developed tumors as early as 
5 weeks, whereas tumors are generally seen by 20-25 weeks in KPC mice. Low-grade 
PanIN lesions appear by 3 weeks in KPCC mice, which might explain early development 
of tumors. Survival analysis indicated significantly reduced survival rate of KPCC mice as 
compared to KPC mice.  
Most KPCC tumors displayed poorly differentiated/undifferentiated histology. 
Quantification of atypical mitotic figures demonstrated increased proliferation of KPCC 
tumors as compared to KPC tumors. Also, IHC staining with alpha-SMA and Sirius red 
indicated decreased stroma in full-blown cancerous regions of KPCC mice as compared 
to KPC mice. Decreased stroma might account for increased aggressiveness of KPCC 
tumors.  
 Early formation of metastatic lesions was seen for KPCC tumors as compared to 
KPC tumors. Tumor metastasis was seen in several organs such as peritoneum and liver. 
KPCC mice showed a remarkable increase in vimentin expression as compared to KPC 
mice, which may account for increased metastasis.  
We next want to determine if observed tumor growth and metastasis is linked to 
altered glycosylation. Glycan analysis showed decreased expression of T carbohydrate 
antigen in tumors of KPCC mice in comparison to KPC mice. On the contrary, expression 
of Tn carbohydrate antigen was significantly increased in KPCC mice as compared to KPC 
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mice. Altogether, this part of the project demonstrates that loss of C1galt1 in PDAC leads 
to truncated glycophenotype and faster PDAC progression and metastasis. 
 
2. Future Directions 
A. Loss of GALNT3 in poorly differentiated cancer leads to increased 
aggressiveness 
(i) Does loss of GALNT3 expression lead to poorly differentiated PDAC or is it a 
consequence of poorly differentiated PDAC? 
Considering that the loss of GALNT3 in well/moderately differentiated PDAC cells leads 
to altered expression of poorly differentiated markers, we questioned if GALNT3 
expression governs PDAC differentiation status. Previous research in thyroid cancer and 
several malignancies have indicated the potential loss of GALNT3 in poorly differentiated 
cancer [17]. Further, we have observed that treatment with IFN-γ and differentiation-
inducing factor, retinoic acid, induced expression of GALNT3 as compared to untreated 
PDAC cells (Figure 6.1). To explore the role of GALNT3 in PDAC differentiation, GALNT3 
over-expression in poorly differentiated PDAC cells such as Panc-1 and MIA PaCa-2 and 
normal pancreatic epithelial cells (HPNE) needs to be performed. Further, generation of a 
KPC mouse model with an inducible knockout of GALNT3 can effectively address its role 
in PDAC. 
 (ii) Does EGFR O-glycosylation impact its function? 
Our results have shown that knockdown of GALNT3 resulted in increased expression of 
truncated glycans on EGFR and Her2, which might account for their increased 
phosphorylation/activation. Using NetOGlyc 4.0 Server, which is a bioinformatics-based 
tool used to predict O-GalNAc sites in mammalian proteins, we identified a few O-
glycosylation sites on Her2. Experimental detection of exact sites of O-glycosylation is a 
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challenging task and needs to be done using comprehensive tools such as a mass 
spectrometry-based glycoproteomic approach. Another unexplored aspect of our study is 
the relative contribution of aberrant glycosylation on the function of these receptors. 
Truncated glycans may relieve steric hindrance posed by extended glycans and thus 
facilitate increased interaction of ErbB receptors among themselves or with other signaling 
proteins. To better understand this, co-immunoprecipitation and reciprocal IP studies with 
known EGFR and Her2 interacting partners need to be performed.   
 
B. C1GALT1 knockout in PDAC cells leads to increased tumor growth and 
metastasis 
(i) What is the clinical relevance of C1GALT1? 
Though we do not have any conclusive results for the clinical significance of C1GALT1 
expression in PDAC, C1GALT1 expression studies in RNA and tissue samples from 
PDAC patients suggest that C1GALT1 expression is lost in a subset of PDAC patients. 
Further, our in vitro and in vivo studies have highlighted the significant impact of loss of 
C1GALT1 on PDAC aggressiveness and survival. These findings suggest that evaluating 
C1GALT1 expression in PDAC patients could predict disease severity and can potentially 
help in better management of patients with PDAC. 
(ii) What is the role of C1GALT1 in pancreatic cancer stem cells? 
 Our in vitro and in vivo studies have established that knockout of C1GALT1 
induces PDAC growth and metastasis. In line with these findings, we also observed 
increased expression of CD44 in C1GALT1-knockout PDAC cells. Interestingly, the 
increased expression of C1GALT1 was observed at several molecular weights that may 
correspond to different splice variants/glycoforms of CD44 (Figure 6.2). Since increased 
expression of CD44 is one of the characteristic features of PDAC cancer stem cells, it will 
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be interesting to investigate if C1GALT1 knockout in PDAC induces altered glycosylation 
on cancer stem cells markers [18, 19]. The importance of cancer stem cells in tumor 
growth and several steps of metastasis has been well described in several studies [20]. 
Analysis of cancer stem cells in control and C1GALT1 knockout PDAC cells could 
potentially unveil the involvement of C1GALT1-mediated truncated glycosylation in cancer 
stem cells and metastasis. 
 
C. Genomic depletion of C1galt1 accelerates PDAC progression and metastasis 
(i) Do pancreatic cells modulate expression of C1GALT1 during PDAC progression? 
Since differential expression of O-glycans has been reported during PDAC progression, it 
can be possible that pancreatic cells modulate expression of glycosyltransferases during 
the course of disease development in order to gain differential glycophenotype and hence 
aggressiveness [6]. Our preliminary results demonstrate that treatment of T3M4 PDAC 
cells with inflammatory cytokines such as IL-4 and IL-6 decrease C1GALT1 expression 
(CHAPTER 4-Figure 17). Another study focused on IgA nephropathy have shown that 
treatment of B cells with TGF-β1 decreases C1GALT1 expression that causes aberrant 
glycosylation of IgA [21]. TGF-beta has been widely used in vitro to induce EMT, whereas 
Inflammatory cytokines such as IL-4 and IL-6 have been shown to play an important role 
in tumor growth.[22-24] Based on these findings, we anticipate that several cues from 
microenvironment modulate C1GALT1 expression during PDAC progression.  
To test this, we could begin with RNA-seq analysis of pancreatic tissues procured 
from KPC progression model at several time points representing low-grade PanINs, high-
grade PanINs, cancer, and metastasis. Our group has identified several differentially 
expressed cytokines and chemokines in PDAC progression. This can be used further to 
check the regulation of C1GALT1 by secretory cues from tumor microenvironment.    
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(ii) Role of C1GALT1 in acinar to ductal metaplasia (ADM) 
Several studies have proposed acinar to ductal metaplasia (ADM) as a key event 
in PDAC initiation [25]. While we haven’t yet performed definite experiments to test the 
possibility of C1GALT1-knockout mediated altered glycosylation on ADM, preliminary IHC 
studies depict expression of amylase (acinar cell marker) in metaplastic ducts from KPCC 
tissues (Figure 6.3). These findings give us a reason to believe that C1GALT1 knockout 
may drive ADM and results in increased cancer aggressiveness.  
Therefore, to explore the prospective involvement of C1GALT1 loss on ADM, we 
could use an in vivo model of ADM well characterized in our lab. Prior studies from our lab 
have very well established that caerulein treatment in KPC mice induces ADM-like 
histology, which eventually progresses to PDAC [26]. Evaluation of C1GALT1 in the RNA 
and tissues samples from control and caerulein-treated KPC mice could ascertain the 
plausible involvement of C1GALT1 role in ADM. 
(iii) Therapeutic studies with KPCC mouse model 
Since the KPCC mouse model represents faster PDAC progression model, it can 
possibly be utilized for therapeutic studies. Knockout of C1GALT1 in PDAC cells resulted 
in increased activation of ErbB receptors, FAK and Akt. All of these signaling proteins 
have been implicated in growth and metastasis of PDAC. Some of the drugs targeting 
these proteins are FDA approved and are in clinical trials for several pathological 
conditions and cancers, including PDAC. For instance, VS-4718 is a clinically available 
FAK inhibitor and has been shown effective for targeting PDAC [27]. Afatinib/Gilotrif is an 
another FDA approved drug for non-small cell lung cancer and several studies from 
various other groups and our lab also supports its use in PDAC [28, 29].  Efficacy of these 
drugs to control PDAC progression and metastasis can be tested in this animal model.  
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 These preclinical studies on mice models could pave the way of targeting PDAC 
in patient samples. We believe that personalized approach should be used for therapeutic 
targeting in PDAC patients. 
219 
 
 
 
Figure legends 
Figure 6.1 Regulation of GALNT3 expression: Western blot demonstrates that pro-
inflammatory cytokine-IFN-γ and differentiation inducing factor-retinoic acid upregulates 
GALNT3 expression in CD18/HPAF PDAC cells
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Figure 6.1 
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Figure 6.2 Differential expression of CD44 in C1GALT1 KO PDAC cells: Western 
blotting demonstrates increased CD44 expression in KO clones as compared to wild-type 
control cells. Further, a number of CD44 bands were seen in C1GALT1 KO cells, which 
might correspond to CD44 glycoforms.
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Figure 6.2 
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Figure 6.3: Amylase expression in KPCC neoplastic ducts: Immunofluorescence 
staining with amylase (acinar cell marker) demonstrates positive staining in KPCC ducts.
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Figure 6.3 
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